



UNIVERSITÀ POLITECNICA DELLE MARCHE  
Repository ISTITUZIONALE

Human pharmaceuticals in marine mussels: Evidence of sneaky environmental hazard along Italian coasts

This is the peer reviewed version of the following article:

*Original*

Human pharmaceuticals in marine mussels: Evidence of sneaky environmental hazard along Italian coasts / Mezzelani, M., Fattorini, D., Gorbi, S., Nigro, M., Regoli, F.. - In: MARINE ENVIRONMENTAL RESEARCH. - ISSN 0141-1136. - STAMPA. - 162:(2020). [10.1016/j.marenvres.2020.105137]

*Availability:*

This version is available at: 11566/286292 since: 2024-04-10T16:17:47Z

*Publisher:*

*Published*

DOI:10.1016/j.marenvres.2020.105137

*Terms of use:*


The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. The use of copyrighted works requires the consent of the rights' holder (author or publisher). Works made available under a Creative Commons license or a Publisher's custom-made license can be used according to the terms and conditions contained therein. See editor's website for further information and terms and conditions.

This item was downloaded from IRIS Università Politecnica delle Marche (<https://iris.univpm.it>). When citing, please refer to the published version.


(Article begins on next page)

## **HIGHLIGHTS**

- Pharmaceuticals are ubiquitously present in tissues of Mediterranean mussels
- Organisms contained drugs of several therapeutic classes
- Carbamazepine was measured in more than 90% of analysed samples
- 91% of analysed mussels contained at least 1 drug, 55% at least 3
- Seasonality had a limited influence on pharmaceuticals bioaccumulation



**DETECTION FREQUENCY(%)**



**SAMPLES**

96%

85%

55%

17%

**N° MOLECULES**



1 **Human pharmaceuticals in marine mussels: evidence of sneaky environmental hazard along**  
2 **Italian coasts**

3

4 Marica Mezzelani<sup>a</sup>, Daniele Fattorini<sup>a,b</sup>, Stefania Gorbi<sup>a,b</sup>, Marco Nigro<sup>c</sup>, Francesco Regoli<sup>a,b\*</sup>

5

6 <sup>a</sup> Dipartimento di Scienze della Vita e dell'Ambiente (DiSVA), Università Politecnica delle Marche,  
7 Ancona, Italy

8 <sup>b</sup> Consorzio Interuniversitario per le Scienze del Mare, CoNISMa, ULR Ancona, Ancona, Italy

9 <sup>c</sup> Dipartimento di Medicina Clinica e Sperimentale, Università di Pisa, Italy

10

11 \* Corresponding Author:

12 Prof. Francesco Regoli

13 Dipartimento di Scienze della Vita e dell'Ambiente (DiSVA),

14 Università Politecnica delle Marche,

15 via Brecce Bianche 60131, Ancona, Italy

16 e-mail: [f.regoli@univpm.it](mailto:f.regoli@univpm.it)

17

18 Competing Financial Interests. All of the authors have read the manuscript in its present form, and  
19 we are all aware of, and accept responsibility for, the manuscript. Authors also declare that there is  
20 no any actual or potential competing financial interest in relation to the work described in this  
21 manuscript.

## 22 Abstract

23 Despite the increasing interest for pharmaceuticals in the marine environment, their  
24 accumulation in wild organisms and consequent environmental hazards are still poorly known. The  
25 Mediterranean Sea is highly challenged by the density of coastal populations, large consumption of  
26 pharmaceuticals and their often limited removal by Wastewater Treatment Plants (WWTPs). In this  
27 respect, the present study aims to provide the first large-scale survey on the distribution of such  
28 contaminants of emerging concern in native mussels, *Mytilus galloprovincialis* from Italian coasts.  
29 Organisms were collected from 14 sites representative of relatively unpolluted marine waters along  
30 the Adriatic and Tyrrhenian Sea and analysed for 9 common pharmaceuticals including Non-Steroidal  
31 Anti-Inflammatory Drugs (NSAIDs: Diclofenac DIC, Ibuprofen IBU, Ketoprofen KET and  
32 Nimesulide NIM), the analgesic Acetaminophen AMP, the antiepileptic Carbamazepine CBZ, the  
33 antihypertensive Valsartan VAL, the anxiolytic Lormetazepam LOR and the antidepressant  
34 Paroxetine PAR. Results indicated the widespread occurrence of the majority of pharmaceuticals in  
35 mussel tissues: CBZ was measured in >90% of analysed samples, followed by VAL (>50%), PAR  
36 (>40%), and DIC (>30%), while only AMP and KET were never detected. Heterogeneous tissue  
37 concentrations ranged from a few units up to hundreds of ng/g (d.w.), while seasonal and interannual  
38 variability, investigated over 4 years, did not highlight any clear temporal trend. Limited differences  
39 obtained between the Adriatic and Tyrrhenian Sea, as well as coastal versus off-shore sampling sites,  
40 suggest that analysed levels of pharmaceuticals in mussels tissues should be considered as baseline  
41 concentrations for organisms collected in unpolluted areas of the Mediterranean. This study provided  
42 the first unambiguous evidence of the widespread occurrence of pharmaceuticals in marine mussels  
43 from Italian coasts, giving novel insights on the potential ecotoxicological hazard from such  
44 compounds in marine species.

45

46

## 47 **Keywords**

48 Pharmaceuticals, Contaminants of Emerging Concern, Bioaccumulation, Mediterranean Sea,  
49 Environmental Hazard

## 50 **1. Introduction**

51 The remarkable progress in human and veterinary pharmacology certainly represented one of  
52 the greatest benefits of the modern society also contributing, however, to the increased occurrence of  
53 pharmaceutical compounds in aquatic environments (Boxall et al. 2012; Erzinger et al. 2013;  
54 Gonzalez-Rey et al. 2015; Burket et al. 2019). Such contaminants of emerging concern have been  
55 detected in seawater and sediments worldwide, with variable levels ranging within ng/L- $\mu$ g/L and  
56 ng/g respectively (Mezzelani et al. 2018a). The most frequently detected compounds are represented  
57 by active principles belonging to steroid hormones, antibiotics, non-steroidal anti-inflammatory drugs  
58 (NSAIDs), psychiatric and cardiovascular drugs (Moreno-González et al. 2015; Ebele et al. 2017;  
59 Desbiolles et al. 2018; Mezzelani et al. 2018a,b; Miller et al. 2018) . Laboratory experiments  
60 suggested the capability of bioindicator species to accumulate various classes of pharmaceuticals and  
61 the onset of deleterious outcomes from molecular up to physiological levels. Depending on the type  
62 and doses, measured alterations included the activation of immune system, modulation of lipid and  
63 oxidative metabolism, onset of genotoxic effects, impairment of endocrine system with adverse  
64 effects in organisms homeostasis, development, behaviour and reproduction (Almeida et al., 2020;  
65 Fabbri and Franzellitti, 2016; Mezzelani et al., 2018a,b; Moreno-González et al. 2015). Although  
66 laboratory studies documented ecotoxicological effects of pharmaceuticals in non-target species, the  
67 field distribution of these compounds in wild marine organisms has been less studied. As  
68 contaminants of emerging concern, pharmaceuticals are not included in any environmental regulation  
69 and neither routinely monitored: among over 4000 substances classified as pharmaceuticals, only  
70 seven (two estrogens, 17- $\alpha$ -ethinylestradiol and 17- $\beta$ -estradiol, and five antibiotics such as  
71 erythromycin, clarithromycin, azithromycin, amoxicillin and ciprofloxacin) are included in a  
72 dynamic watch-list of the European Union Water Framework Directive (2018/840/EU), based on

73 their potential adverse effects for aquatic ecosystem (Miller et al. 2018). Recently, the European  
74 Commission (EC) acknowledged the importance of environmental pharmaceuticals, and on March  
75 2019 a Communication was adopted outlining a set of actions toward the multifaceted challenges of  
76 those residues in natural ecosystems. The "Strategic Approach to Pharmaceuticals in the  
77 Environment" (COM/2019/128 final) emphasizes the need of gathering monitoring data as an  
78 important prerequisite to develop an appropriate risk assessment of such emerging pollutants.

79         Pharmaceutically active compounds are typically designed to cross biological membranes and  
80 various compounds belonging to the most common therapeutic classes (i.e. antibiotics, psychiatric,  
81 anti-inflammatory, cardiovascular drugs, etc.) have been detected in aquatic biota. The majority of  
82 studies focussed on riverine and lacustrine fauna, and fish species have been preferentially  
83 investigated in comparison to molluscs and other invertebrates (Liu et al. 2015; Burket et al. 2019;  
84 Miller et al. 2019). This is a crucial aspect since concentrations of antibiotics and antidepressants in  
85 bivalves can be one order of magnitude higher than those measured in fish from the same sampling  
86 area (Du et al. 2014).

87         Only a few studies were carried out on species living in coastal areas (Huerta et al., 2012;  
88 Martinez-Bueno et al., 2014; Maruya et al., 2014; Alvarez-Muñoz et al., 2015a,b; Serra-Compte et  
89 al., 2017; Martinez-Morcillo et al., 2020). A variable accumulation of eighteen compounds was  
90 reported in fish and molluscs from the Mar Menor Lagoon (Moreno-González et al. 2016) and  
91 pharmaceuticals were also detected in *Mytilus* spp. from Adriatic Sea, Belgian and Portuguese  
92 Atlantic coasts (Wille et al. 2011; Mezzelani et al. 2016a; Cunha et al. 2017). The Mediterranean Sea  
93 is the largest enclosed sea, highly challenged by elevated anthropogenic pressures, with reported  
94 impacts from human activities proportionally stronger than in any other sea (Coll et al. 2012; Suaria  
95 et al. 2016). The density of population inhabiting coastal areas, the large consumption of  
96 pharmaceuticals for both human and veterinary medicine, and the often inadequate presence or  
97 typology of wastewater treatment plants (WWTPs) make the Mediterranean an ideal basin for  
98 investigating the occurrence and distribution of pharmaceutical compounds in marine organisms. The

99 common Mediterranean mussel, *Mytilus galloprovincialis*, is one of the most widely used sentinel  
100 organisms with a marked capability to bioaccumulate xenobiotics and to exhibit sensitive molecular  
101 and cellular responses to such stressors (Canesi et al, 2007; Beyer et al. 2017; Oliveira et al. 2017;  
102 Regoli et al. 2014, 2019; Swiacka et al., 2019). In addition, considering the extensive mussels farms  
103 along the coasts, assessment of pharmaceuticals residues in these organisms is relevant also in terms  
104 of potential human exposure through food consumption, (Wille et al., 2011; Alvarez-Muñoz et al.,  
105 2015a,b; Serra-Compte et al., 2017; Martinez-Morcillo et al., 2020).

106 The aims of this study were (i) to investigate how widespread is the occurrence of  
107 pharmaceuticals in tissues of wild mussels along the Adriatic and Tyrrhenian Sea (Figure 1), (ii) to  
108 highlight seasonal and interannual fluctuations and (iii) to evaluate differences between coastal and  
109 off-shore locations. In this respect, concentrations of model pharmaceuticals were measured in wild  
110 mussels collected from a total of 14 sites along the Adriatic and Tyrrhenian Sea. In 3 sites of the  
111 Central Adriatic, samplings were carried out over 4 years to better characterize baseline levels and  
112 the presence of seasonal or inter-annual patterns of variation. The selected compounds included 9  
113 among the most commonly used active principles in Italy, representative of different therapeutic  
114 classes such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) with Diclofenac (DIC), Ibuprofen  
115 (IBU), Ketoprofen (KET) and Nimesulide (NIM), analgesics with Acetaminophen (AMP), and  
116 psychiatric drugs with the antiepileptic carbamazepine (CBZ), the hypnotic-sedative lormetazepam  
117 (LOR), the antidepressant paroxetine (PAR); the antihypertensives valsartan (VAL).

118 Considering the paucity of data on bioaccumulation of pharmaceutical compounds in marine  
119 organisms, this study represents the first large and temporal scale survey for the Mediterranean.  
120 Obtained results were expected to provide novel insights on the potential risk of such emerging  
121 environmental contaminants, aimed to effectively implement knowledge-based reduction and  
122 prevention measures.

123123

## 124 2. Materials and Methods

### 125 2.1 Sampling activities

126 Sampling activities were designed to fulfil the three objectives of the present study: spatial,  
127 temporal and coastal vs off-shore evaluations. The collection of common mussels is not subjected to  
128 ethical review permissions according to both European and Italian normative (Directive 2010/63/UE,  
129 Italian Legislative Decree n. 26, 4/03/2014) and monitoring guidelines widely recommend this  
130 species as an appropriate bioindicator for assessing bioavailability of environmental pollutants and  
131 their possible transfer to humans through food consumption (Beyer et al. 2017).

132 Individuals of the Mediterranean mussels, *M. galloprovincialis* of homogeneous dimensions  
133 ( $5.0 \pm 1.0$  cm shell length) were seasonally collected, from 2014 to 2017, in three different sites of  
134 the central Adriatic coast namely Senigallia (S1), Torrette (S2) and Portonovo (S3), in the district of  
135 Marche region (Figure 1 and Table SM1 for additional information). Selected sites are representative  
136 of relatively unpolluted coastal areas, where local authorities regularly monitor the presence of  
137 traditional pollutants to detect environmental disturbance. Those sites are typical summer touristic  
138 destinations which since several years, are awarded with the Blue Flag certification by the Foundation  
139 for Environmental Education, assigned to beaches, marinas, and sustainable boating tourism  
140 operators as an indication of their high environmental and quality standards. Mussels are farmed for  
141 human consumption in S1 and S3; those from site S3, widely characterized for the seasonal  
142 fluctuations of trace elements and biological responses to stressful conditions (Bocchetti and Regoli,  
143 2006; Fattorini et al., 2008; Pisanelli et al., 2009), represent a well-known reference population to use  
144 in environmental studies. For each sampling site and period, mussels were collected and the whole  
145 tissues were removed from 50 specimens, pooled in 10 samples (each containing 5 organisms), and  
146 stored at  $-20$  °C until the chemical analyses on pharmaceuticals concentrations.

147 Additional 11 sampling sites were selected along the Adriatic and Tyrrhenian coasts, to  
148 increase the information on a larger geographical scale (Figure 1 and Table SM1 for additional

149 information). Adriatic coastal sites included a natural park (S4), the entrance of Pesaro canal harbour  
150 (S5), and a mussel farm (S7), while off-shore locations were a 10 m depth artificial reef for fish  
151 repopulation at about 7 nautical miles (NM) from the coast (S6), and a gas platform at 10 NM offshore  
152 (S8): mussels were collected on July 2016 (S7-S8) and on May, July and September 2017 (S4-S6).  
153 The Tyrrhenian sites, located along the coasts of Liguria and Tuscany regions, were representatives  
154 of a mussel farm (S9), natural parks influenced by rivers runoffs (S10-S11), non-industrial harbour  
155 (S12), touristic areas with recreational beaches (S13-S14). Mussels were collected on December 2016  
156 (S9, S10, S11, S12), September 2017 (S12), March and August 2017 (S13, S14). For each sampling  
157 site and period, the whole tissues were removed from 25 mussels, pooled in 5 samples (each  
158 containing 5 organisms), and stored at -20 °C until the chemical analyses.

159159

## 160 *2.2 Chemical analyses*

161 Levels of AMP, CBZ, DIC, IBU, KET, LOR, NIM, PAR and VAL in mussels tissues were  
162 determined on 5 replicates, each constituted by whole tissues of 5 specimens. Measurement of tissue  
163 levels of CBZ, PAR, LOR and VAL could be performed in mussels collected after July 2015 when  
164 analytical protocols were developed and validated for such compounds. Sample preparation and  
165 analytical determination followed a modification of previously validated methods which allow the  
166 sensitive detection of investigated molecules through a High Performance Liquid Chromatography  
167 (HPLC) approach with fluorimetric and diode array detection (Mezzelani et al. 2016a,b; Mezzelani  
168 et al. 2018b). Such analytical methods are detailed in Supplementary Materials (SM) with a complete  
169 description of homogenization and extraction buffers used for various compounds, solid phase  
170 extraction (SPE) procedures, conditions for chromatographic separations and peaks detection, limits  
171 of detection and quantification of individual molecules (SM Tables SM2, SM3, SM4).

172 Concentrations of various pharmaceuticals were quantified by comparison with signals of  
173 pure standard solutions. Due to the lack of appropriate Certified Standard Reference Materials

174 (SRMs), recovery for each compound was estimated on samples of control mussels (n=5) spiked with  
175 various concentrations of investigated molecules, as described in detail in the SM. The optimal  
176 working range corresponded to the analytical limit of measurement which guarantees an acceptable  
177 variability (CV<20%) on 10 replicates and a good linearity ( $R^2 \geq 0.99$ ), assuring at least 95% of  
178 recovery. The intensive validation of the method carried out for the control of precision, accuracy,  
179 variability and analytical recovery did not require the further use of internal standards, preventing the  
180 intrinsic difficulty of identifying suitable surrogate substances for HPLC-DAD analytical methods.  
181 The water content in mussel tissues was determined by the measurement of wet weight and dry weight  
182 ratio in 5 replicates (each constituted by 5 organisms), for each sampling period and site; final  
183 concentrations of detected pharmaceuticals were normalized and expressed as ng/g dry weight (d.w.).

184         Considering the analytical conditions and the preparation procedures described in SM, the  
185 minimum measurable amounts in mussels tissues (Limit of Quantification, LOQ) were 1 ng/g dry  
186 weight (d.w.) for AMP, 1.37 ng/g d.w. for DIC, 8 ng/g d.w. for IBU, 0.86 ng/g d.w. for KET, 2.10  
187 ng/g d.w. for NIM, 1.03 ng/g d.w. for CBZ, 0.43 ng/g d.w. for LOR, 0.95 ng/g d.w. for PAR and 0.49  
188 ng/g d.w. for VAL, as described in detail in the SM and reported in the Table SM2.

189189

### 190 2.3 Statistical analyses

191         Differences between tissue concentrations of pharmaceuticals were tested for S1, S2 and S3  
192 by two-way analysis of variance (ANOVA) considering the factors “month”, “year” and the  
193 interaction of the two factors (IBM SPSS Statistics). Values <LOQ were computed using half of the  
194 LOQ, data were normalized, and the homogeneity of variance was checked by the Levene’s test at  
195 the 95% of confidence interval. Given the high variability measured in tissues concentrations during  
196 months and years, for each site the criteria adopted prior to test ANOVA were (i) tissue concentrations  
197 > LOQ in at least 3 different months, (ii) tissue concentrations > LOQ in at least 3 different years.  
198 When statistically significant differences were obtained from the two-way ANOVA analysis, the

199 Student-Newman-Keuls *post-hoc* comparison (SNK) was applied to discriminate between means of  
200 values, at the 95% of confidence interval. In addition, one-way analyses of variance (ANOVA) was  
201 applied to test differences of pharmaceuticals concentrations between mussels collected from all the  
202 Adriatic and Tyrrhenian sites (S1-S14).

203 A non-metric Multi-Dimensional Scaling (nMDS) was performed as multivariate ordination  
204 analysis in which variables describing a multidimensional space are scaled on a two-dimension plot  
205 based on their similarity, thus maximizing the distance among points (Clarke and Gorley, 2001). The  
206 nMDS function from the Vegan R-package (Oksanen et al. 2011) was applied on bioaccumulation  
207 levels of DIC, IBU, NIM, CBZ, PAR, LOR and VAL measured in mussels sampled from S1-S2-S3  
208 in 2015-2016-2017.

209

### 210 3. Results

211 Tissue concentrations of individual pharmaceuticals, the sum of Non-Steroidal Anti-  
212 inflammatory Drugs,  $\sum$ NSAIDs (DIC, IBU, NIM), and the sum of Psychiatric drugs  $\sum$ PSY (CBZ,  
213 PAR, LOR) measured in different months and years in mussels from S1, S2 and S3 are reported in  
214 Table 1. Results of analysis of variance revealed significant differences related to “month” and “year”  
215 (Supplementary Material Table 6, SM6). Among NSAIDs, DIC was the most frequently detected  
216 compound with concentrations ranging from below 1.40 to more than 170 ng/g (dry weight of the  
217 tissues, d.w.). Significant temporal variations were observed only in mussels from S1 with higher  
218 DIC levels in July 2015, May and October 2016, May 2017 ( $p < 0.001$ , Table 1). The elevated  
219 variability of results obtained in S2 and S3 prevented to reach a statistical significance despite the  
220 higher values were always measured between late spring and early autumn, particularly in the  
221 recreational beach (S3) during the touristic season. In all the sites, DIC was typically below detection  
222 limit in autumn and winter months (September, November, February, Table 1). IBU and NIM were  
223 occasionally measured with spotted peaks of concentrations ranging from less than 8 to more than  
224 140 ng/g (d.w.), and from  $<2$  to more than 80 ng/g (d.w.), respectively (Table 1): such fluctuations

225 did not appear to be related to any seasonal cycle. Levels of AMP and KET were always below the  
226 limit of quantification (LOQ), of 1 ng/g (d.w.) and 0.86 ng/g (d.w.) respectively (data not shown).  
227 The  $\Sigma$ NSAIDs was given as the sum of tissue levels of DIC, IBU and NIM, expressed as nmol/g to  
228 normalize different molecular weights of these compounds. Although the general trend of  $\Sigma$ NSAIDs  
229 was mostly influenced by DIC, overall it highlighted that in almost all sampling periods mussels  
230 contained at least one residue of this pharmaceutical class.

231 CBZ was detected in more than 95% of analysed samples, being generally the most abundant  
232 among measured pharmaceuticals with mean values ranging from 35 up to 280 ng/g (d.w.) (Table 1).  
233 The significant differences observed as a function of “month” and “year” (Table SM6) did not  
234 highlight a clear seasonality of CBZ concentrations, although lower average values were detected in  
235 Summer (July and August of various years, Table 1). Concentrations of PAR in mussels were  
236 detectable in all the sites for most of the periods, typically ranging between 2 and 10 ng/g (d.w.), and  
237 with significantly higher values in S1 in July 2015 and 2016 (up to 30 ng/g d.w.), and in S3 in July  
238 2017 (up to 50 ng/g, Table 1). Tissue levels of LOR were characterized by an elevated variability,  
239 both in terms of occurrence in different sites/periods, and of concentrations ranging from a few up to  
240 300 ng/g (d.w.) (Table 1).

241 The sum of concentrations measured for CBZ, PAR and LOR ( $\Sigma$ PSY) confirmed the  
242 variability already reported for individual compounds, further highlighting the presence of psychiatric  
243 drugs in mussels tissues in all the sites and sampling periods (Table 1). Finally, the antihypertensive  
244 VAL was detectable in the majority of analysed samples with tissue levels from less than 0.5 to  
245 approximately 7 ng/g (d.w.) (Table 1).

246 With the only exception of AMP and KET always below the detection limit, the Non Metric  
247 Multidimensional Scaling analyses (nMDS) was carried out on all pharmaceutical compounds  
248 measured in different periods (2015-2017) and sites (S1-S3): a rather moderate separation was shown  
249 among variables, supporting previous evidences of a limited influence of seasonality on  
250 pharmaceuticals concentrations in mussels tissues (Figure 2). Based on this evidence, average tissues

251 concentrations of individual pharmaceuticals,  $\Sigma$ NSAIDs (DIC, IBU, NIM), and  $\Sigma$ PSY (CBZ, PAR  
252 and LOR) were calculated for mussels collected from all the Adriatic and Tyrrhenian locations, and  
253 the comparison between sites was thus irrespective of sampling month (Figure 3). The obtained  
254 results revealed the widespread bioaccumulation of all the investigated pharmaceuticals in mussels  
255 from all the sites (Figure 3). Despite some geographical differences, the concentrations were not  
256 significantly different (one-way ANOVA) between mussels from Adriatic and Tyrrhenian locations  
257 (S1-S8 and S9-S14, respectively): the overall range of measured concentrations was comparable to  
258 that characterized for S1-S3 on a seasonal/interannual basis, and no evident differences occurred from  
259 coastal toward off-shore sites, S6-S8 (one-way ANOVA).

260 The relative frequency of pharmaceuticals detection in mussels collected from all sampling  
261 sites and periods is summarized in Figure 4A. CBZ occurred in more than 90% of analysed organisms,  
262 VAL in 52%, followed by PAR and LOR, 43 and 41% respectively. Among NSAIDs, DIC was  
263 measured in 31% of samples, while KET and AMP were always below the LOQ (Fig 4). Overall, the  
264 96% of samples contained at least 1 active principle, the 85% at least 2, and 55% at least three of the  
265 analysed pharmaceutically active compounds (Fig.4B).

266266

## 267 **4. Discussion**

### 268 *4.1. Occurrence of pharmaceuticals in mussels tissues*

269 The large consumption of pharmaceuticals is posing an important global issue and despite  
270 scientific research has been active for 20 years, the environmental relevance of this problem is still  
271 unclear and not adequately considered at political and regulatory levels. In this respect, scientific data  
272 should support political authorities in developing reliable normative guidelines, appropriate strategies  
273 for environmental risk assessment, knowledge-based reduction and prevention measures.  
274 Pharmaceuticals are characterized by a complex environmental fate modulated by their excretion rate  
275 after human or veterinary usage, improper domestic disposal, limited removal by WWTPs,

276 particularly under specific environmental conditions which influence the consequent transport into  
277 and across aquatic bodies. Research progress contributed to extensively document the presence of  
278 pharmaceuticals in wastewaters, rivers, lakes, coastal water and sediments, but such data do not  
279 provide specific information on biological hazards to organisms and ecosystems (Miller et al. 2019).  
280 Studies to clarify the bioaccumulation of pharmaceuticals in field conditions are recommended by  
281 international Authorities (i.e. European Commission, COM/2019/128 final), although this approach  
282 is often hampered by the complexity to identify molecules to prioritize, and limited availability of  
283 analytical protocols. The improvement of extraction methods and of advanced analytical techniques,  
284 such as gas chromatography-tandem mass spectrometry (GC-MS/MS) and liquid chromatography-  
285 tandem mass spectrometry (LC MS/MS), has recently increased the possibility to detect the  
286 distribution of pharmaceuticals, enabling the simultaneous determination of more than 20 compounds  
287 even in complex, environmental samples (Klosterhaus et al. 2013; Martínez Bueno et al. 2013; Miller  
288 et al. 2019). These approaches are fundamental especially when it is necessary to ensure elevated and  
289 certified analytical sensitivity, as for residues in food matrices. However, due to the elevated costs,  
290 the presence and application of such sophisticated analytical methodologies is still limited in many  
291 environmental laboratories involved in routinely biomonitoring activities on marine species (Dodder  
292 et al. 2014; Mc Eneff et al. 2014; Álvarez-Muñoz et al. 2015; Moreno-González et al. 2016 Cunha et  
293 al. 2017). In this respect, considering the urgent need to fill the gap of knowledge on pharmaceuticals  
294 in the aquatic ecosystem (COM/2019/128 final), the possibility to apply a commonly used analytical  
295 approach, despite more time-consuming, can represent an important alternative to increase available  
296 data on the presence of such compounds in marine organisms and to raise public awareness. In the  
297 present study we used specific HPLC analyses with diode array and fluorescence detection which  
298 represent an update and implementation of previously reported methods (Mezzelani et al., 2016a,b,  
299 2018a). Presented protocols, optimized for the measurement of representative classes of drugs, have  
300 been extensively tested in terms of extraction, purification, chromatographic separation and detection,

301 to maximize recovery and to guarantee an environmentally appropriate sensitivity (see  
302 Supplementary Material).

303 Based on our knowledge, the present study represents the largest temporal- and spatial-scale  
304 investigation on the occurrence of pharmaceuticals in Mediterranean mussels, covering 9  
305 pharmaceuticals of 6 therapeutic classes, 14 sites, two basins and 4 years, contributing to provide an  
306 important volume of data on the occurrence of these emerging substances in the marine ecosystems  
307 and on the bioaccumulation capacity of benthic species.

308 Besides specific peculiarities, all the sampling areas sustain several goods and ecosystem  
309 services spanning from leisure and recreational activities (i.e. touristic beaches) to food production  
310 (mussels farms): none of selected sites was close to specific sources like WWTPs discharges.

311 The pharmaceuticals investigated in the present study were selected as model compounds  
312 within the most consumed therapeutic classes in Italy, which include analgesics, anti-inflammatories,  
313 antidepressants, anxiolytics, anticonvulsants and anti-hypertensives (OsMed, 2017). The obtained  
314 results clearly revealed the ubiquitous occurrence of pharmaceuticals in mussels collected in different  
315 sites and periods of unpolluted coastal areas of Italy. Considering NSAIDs, DIC was detected in more  
316 than 30% of samples, showing a wide interval of concentrations, ranging from 1.21 up to 280 ng/g.  
317 Lower values (0.5-4.6 ng/g) were previously detected in *M. galloprovincialis* transplanted in a North  
318 West Adriatic Coastal Lagoon (Pialassa Piomboni) and *Mytilus* spp. from the Portuguese and Irish  
319 coasts (McEneff et al., 2014; Capolupo et al., 2017; Cunha et al. 2017). In fish species DIC was  
320 measured in golden grey mullets (*Liza aurata*) and flounders *P. flesus* from the Mar Menor lagoon,  
321 Tagus and Scheldt estuaries, (Alvarez-Muñoz et al., 2015a; Moreno-Gonzalez et al. 2016). Notably,  
322 despite diclofenac is one of the most frequently detected pharmaceuticals in water column or  
323 sediments and deeply studied for the deleterious effects to wildlife (Oaks et al. 2004; Bonnefille et  
324 al. 2018; Mezzelani et al. 2018a), it has been recently removed from the last update of the European  
325 Watch List (2018/840/EU).

326 Limited information is available on occurrence of NIM and IBU in marine organisms,  
327 confirming the importance to increase availability of data on bioaccumulation of environmental  
328 pharmaceuticals. Our data showed the presence of these compounds in 15.1 and 9.3 % of samples  
329 with values between a few up to several tenths of ng/g. Levels of IBU below the LOQ were observed  
330 in *Geukensia demissa* from the San Francisco Bay (Klosterhaus et al. 2013), while lacustrine fish  
331 species exhibited concentrations up to 62 ng/g (Xie et al. 2017), comparable to mean values measured  
332 in mussels from the present study.

333 AMP and KET were the only pharmaceuticals always below their LOQ. Similar results were  
334 obtained for KET in *M. edulis* from the Baltic Sea (Wolecki et al. 2019), while AMP was detected in  
335 *M. edulis* caged along the Belgian coastline (up to 115 ng/g, Wille et al.2011), in the same species  
336 from the Gulf of Gdansk (up to 80 ng/g, Caban et al. 2016), and in the freshwater *C. fluminea* sampled  
337 close to a WWTP effluent (up to 347 ng/g, Burket et al. 2019). Recent laboratory experiments with  
338 *M. galloprovincialis* highlighted the lack of accumulation for both KET and AMP, but the  
339 contemporary onset of molecular, biochemical and cellular alterations; these results allowed to  
340 hypothesize the potential biotransformation capability by Mediterranean mussels (Mezzelani et al.  
341 2016a,b; 2018b), thus suggesting species-specific differences in bioaccumulation and metabolism of  
342 these pharmaceuticals.

343 Among the investigated drugs, CBZ was by far characterized by the highest frequency of  
344 detection in Mediterranean mussels, being measured in more than 90% of samples. The widespread  
345 distribution of this antiepileptic drug in aquatic environment is documented and related to its  
346 refractory properties, such as resistance to conventional water treatments (coagulation, flocculation,  
347 sand filtration, chlorination), biotreatments and photodegradation (Zhu et al. 2019). The half-life of  
348 CBZ in water column requires between 4.5 and 25 sunny summer days for degradation through direct  
349 photolysis (Calisto et al. 2011), while exposure to sunlight in winter or at higher latitudes (50°N)  
350 determines a persistence in aquatic environments greater than 100 days (Andreozzi et al. 2003;  
351 Oliveira et al. 2017); laboratory and field investigations defined an average half-life of CBZ >200

352 days, with a maximum of 1200 days in a Swedish lake (Bu et al. 2016; Zou et al. 2015). Tissue  
353 concentrations measured in *M. galloprovincialis* from the Adriatic and Tyrrhenian sites (30-300 ng/g)  
354 are at least one order of magnitude higher than those reported for mussels farmed in Southeastern  
355 France (up to 3.5 ng/g d.w., Martínez Bueno et al. 2013), in caged *M. edulis* deployed for 6- months  
356 along the Belgian coast (up to 11 ng/g, Wille et al. 2011), in *G. demissa* from San Francisco Bay (2.4  
357 ng/g, Klosterhaus et al. 2013), in *Cassostrea gigas* from Ebro delta ( $2.1 \pm 0.04$  ng/g (d.w.)), Álvarez-  
358 Muñoz et al. 2015). The high concentrations and frequency of CBZ in Mediterranean mussels  
359 highlight an elevated pressure and concern for this antiepileptic drug, the toxicological effects of  
360 which have been reported for non-target marine organisms (Freitas et al. 2016; Oliveira et al. 2017;  
361 Mezzelani et al. 2018b).

362 Our study also documented for the first time an elevated occurrence of PAR and LOR, both  
363 detected in more than 40% of analysed mussels with tissue levels typically below 10 ng/g (d.w.) and  
364 frequent peaks up to 50 ng/g (d.w.). Also for these compounds, no information is actually available  
365 on potential accumulation in marine species: levels of PAR were <LOQ in *M. galloprovincialis* from  
366 the Portuguese coast, while no data were reported for LOR (Moreno-Gonzalez et al. 2016). PAR is a  
367 typical antidepressant belonging to the Selective serotonin reuptake inhibitors (SSRIs), while LOR is  
368 a Benzodiazepine (BZP) prescribed for its anxiolytic, hypnotic and tranquilizer properties. Within  
369 such therapeutical classes, PAR and LOR are the most prescribed active principles in Italy (OsMed,  
370 2017); consumption of LOR increased by more than 10 folds from 1983 to 2017, representing the  
371 only BZP with this atypical trend, and virtually replacing the usage of the other similar active  
372 principles (Faccini et al. 2012).

373 More than 50% of analysed organisms also showed the presence of VAL, an angiotensin II  
374 receptor antagonist, usually prescribed as anti-hypertensive. Despite frequently detected in water  
375 column (Gros et al. 2012; Klosterhaus et al. 2013; Moreno-González et al. 2015; Pereira et al. 2015;  
376 Alygizakis et al. 2016; Mezzelani et al. 2018a; Mijangos et al., 2018), only one study documented its  
377 accumulation in the freshwater annelid *Erpobdella octoculata* with levels up to 2.3 ng/g (Grabicova

378 et al. 2015), rather comparable to those measured in Adriatic and Tyrrhenian mussels: no data,  
379 however, is actually available on its potential adverse effects on marine organisms.

380 Similarly, to LOR and PAR, also VAL is the main active principle consumed in Italy within  
381 its therapeutical class. These compounds are scarcely detected in marine and freshwater environments  
382 worldwide (Salgado et al. 2011; De Solla et al. 2016; Mole and Brooks, 2019). Their widespread  
383 distribution in mussels from Italian coasts, may thus suggest that national prescribing and sale trends  
384 directly affect the fate of such compounds in environment and biota, reinforcing the concept that the  
385 life-cycle of pharmaceuticals does not end with their usage (Peake et al. 2016).

386386

#### 387 *4.2. Seasonal and geographical differences of pharmaceuticals in mussels tissues*

388 The seasonal and interannual analyses carried out for almost 4 years in mussels from 3  
389 Adriatic sites (S1-S3) did not highlight any clear temporal trend in pharmaceuticals bioaccumulation,  
390 in spite of the significant differences among months and years (Two-Way ANOVA, Table SM6).  
391 Compared to concentration of other chemical pollutants which are influenced by reproductive cycle  
392 of organisms (Fattorini et al., 2008), seasonal variations of pharmaceuticals in marine species were  
393 not observed in tissues of different wild species sampled from Mar Menor Lagoon in spring and  
394 autumn (Moreno-González et al. 2016). Nonetheless, in our study lower tissue levels of CBZ detected  
395 in summer periods (July and August) would agree with a greater photolytic degradation of this drug  
396 at higher seawater temperature and solar irradiation, (Andreozzi et al. 2003). At the same time, some  
397 peaks observed for other pharmaceuticals (NIM, LOR, PAR) during the summer months (July and  
398 August), suggest the impact of a greater anthropogenic pressure in touristic areas. However, the  
399 elevated variability of results also confirms the complexity of factors modulating the release,  
400 persistence and bioavailability of such molecules in the marine environment (Cui et al. 2016). Among  
401 these, extreme hydrological events, rivers runoff, flow rates and efficiency of WWTPs influence the  
402 irregular inputs of pharmaceutically active compounds in coastal areas, while environmental factors  
403 such as seawater temperature, pH and solar irradiation can affect stability and intrinsic chemical-

404 physical properties of active principles (Ebele et al. 2017; Väitalo et al. 2017). The unpredictable  
405 interactions among so many variables can determine a constant but heterogeneous distribution of  
406 pharmaceuticals in coastal organisms.

407         The comparison of mussels from all the sites revealed a similar pattern of pharmaceuticals  
408 accumulation, without significant dissimilarities in various geographical areas. Despite the different  
409 oceanographic and hydrographic characteristics, Adriatic and Tyrrhenian basins are both affected by  
410 freshwater inputs from the Po river and Arno river, respectively (Giovanardi et al. 2018). The Po  
411 River is the main Italian watercourse, flows in Northern Italy through some of the most anthropized  
412 Italian regions. Its surface extends for over 71.000 Km<sup>2</sup>, crossing 3.200 municipalities with around  
413 16 million inhabitants and receiving civil, industrial and agricultural effluents. The Arno river has a  
414 lower extension (9.000 Km<sup>2</sup>) affecting 164 municipalities with more than 2 million inhabitants and it  
415 receives mostly civil and industrial effluents. All the sites investigated in the present study reflected  
416 common typologies of coastal sites, sustaining different ecosystemic services including protected  
417 areas, recreational and touristic beaches, mussel farms, small marinas and non-industrial harbours:  
418 the common characteristic of the sampled locations was the lack of specific sources for  
419 pharmaceuticals release. To our knowledge no information on concentrations in water column are  
420 available for the selected compounds in sampling sites and obtained results can be considered as  
421 baseline levels of pharmaceuticals accumulation in Mediterranean mussels; this hypothesis is further  
422 supported by similar levels of drugs measured in mussels from coastal sites and those collected at 5-  
423 10 NM offshore.

424         The ubiquitous occurrence of pharmaceuticals in tissues of *M. galloprovincialis* confirmed  
425 the capability of these non-target organisms to accumulate such compounds, clearly reflecting an  
426 environmental side effect of massive consumption of medicines, their limited removal from  
427 wastewater treatment plants and consequent release into the aquatic environments (Hernando et al.  
428 2006; Ankley et al. 2007; Kay et al. 2017). Such results highlight the importance to improve  
429 pharmaceuticals characterization in marine species on a global scale, applying all available and

430 reliable analytical procedures. Worthy to note is the constant co-exposure of *M. galloprovincialis* to  
431 multiple pharmaceuticals, evidenced by more than 55% of samples containing simultaneously at least  
432 3 of analysed compounds: this result highlight the urgent need to consider pharmaceutical  
433 contaminants as mixtures potentially exacerbating the consequences on aquatic species through the  
434 onset of additive or synergistic effects (Giuliani et al., 2013; Ding et al. 2016; Freitas et al. 2016;  
435 Godoy et al. 2019; Trombini et al. 2019). Although concentrations measured in this study are far from  
436 human therapeutic doses of administration, and estimation of possible hazard for human consumption  
437 was outside the scope of this work, nonetheless it should be noted that accumulation of similar levels  
438 of DIC, IBU and NIM in mussels, was shown to modulate the appearance of subtle biological effects  
439 spanning from changes of transcriptional profile to immune responses, genotoxicity, alterations of  
440 lipid metabolism, oxidative and neurotoxic effects (Mezzelani et al. 2016a,b; Mezzelani et al. 2018b).

441441

## 442 5. Conclusions

443 This study demonstrated the ubiquitous presence of pharmaceuticals in mussels tissues from  
444 the Mediterranean, suggesting a baseline occurrence of these contaminants of emerging concern. The  
445 large temporal- and spatial-scale analysis of multiple compounds demonstrated the contemporary  
446 accumulation of pharmaceuticals belonging to different therapeutic classes. 91% of analysed mussels  
447 contained at least 1 of the investigated drugs, and 55% at least 3; carbamazepine was the most  
448 frequent, being detected in more than 90% of analysed samples. Considering the limited number of  
449 pharmaceuticals selected in this study on the total of prescribed compounds, the concern on such  
450 environmental contaminants should be raised, promoting more frequent monitoring campaigns, even  
451 with the use of simple but reliable analytical approaches. Overall results support the need to prioritize  
452 pharmaceutical compounds for an appropriate environmental risk assessment in aquatic ecosystems,  
453 actually recognised as a priority from scientists, European Commission (COM/2019/128 final), the  
454 United Nations Agenda 2030, the G7/G20 and World Health Organisation. Such a challenging issue  
455 requires a multidisciplinary approach to integrate different competences and perspectives: scientists

456 need to better elucidate environmental fate and mechanisms of action of pharmaceuticals in non-  
457 target organisms, contributing to raise public awareness and to promote adequate behaviours. At the  
458 same time, medical doctors might consider the environmental fate and hazard of different active  
459 principles when prescribing drugs, thus stimulating also pharmaceutical industries toward a  
460 sustainable innovation combining therapeutical efficacy with environmental impact of new  
461 molecules. Finally, reliable normative guidelines should be recognized as technological opportunities  
462 for designing new wastewater treatment processes and plants, to improve removal efficiency and  
463 decrease the input of pharmaceuticals in aquatic bodies.

464464

465 **Acknowledgements.** This research was partially supported by the Polytechnic University of Marche  
466 (UNIVPM) that financed the post-doc and PhD fellowships for Marica Mezzelani. We thank Dr. V.  
467 Proposito (Central Narcotics Office, General Directorate of Medical Devices and Pharmaceutical  
468 Service, Italian Ministry of Health), for her support to obtain the authorization for experimental-  
469 scientific use of standards containing narcotic drugs or psychotropic substances. We also thank the  
470 students Luca Cirino and Riccardo Ceccarelli for their support during sampling and laboratory  
471 analyses.

472472

473473

## 474 **References**

- 475 1. Almeida, A., Silva, M.G., Soares, A. M. V. M., Freitas, R. 2020. Concentrations levels and  
476 effects of 17alpha-Ethinylestradiol in freshwater and marine waters and bivalves: A review.  
477 Environ. Res. 185, 109316. <https://doi.org/10.1016/j.envres.2020.109316>
- 478 2. Álvarez-Muñoz, D., Rodríguez-Mozaz, S., Maulvault, A.L., Tediosi, A., Fernández-Tejedor,  
479 M., Van den Heuvel, F., Kotterman, M., Marques, A., Barceló, D., 2015a. Occurrence of  
480 pharmaceuticals and endocrine disrupting compounds in macroalgae, bivalves, and fish from

- 481 coastal areas in Europe. Environ. Res. 143, 56–64.  
482 <https://doi.org/10.1016/j.envres.2015.09.018>
- 483 3. Alvarez-Muñoz, D., Huerta, B., Fernandez-Tejedor, M., Rodríguez-Mozaz, S., Barceló, D.,  
484 2015b. Multi-residue method for the analysis of pharmaceuticals and some of their  
485 metabolites in bivalves. Talanta 136 174-2. <https://doi.org/10.1016/j.talanta.2014.12.035>
- 486 4. Alygizakis, N.A., Ferrero, P.G., Borova, V.L., Pavlidou, A., Hatzianestis, I., Thomaidis, N.S.,  
487 2016. Occurrence and spatial distribution of 158 pharmaceuticals, drugs of abuse and related  
488 metabolites in offshore seawater. Sci. Total Environ. 541, 1097–1105  
489 <https://doi.org/10.1016/j.scitotenv.2015.09.145>
- 490 5. Andreozzi, R., Raffaele, M., Nicklas, P., 2003. Pharmaceuticals in STP effluents and their  
491 solar photodegradation in aquatic environment. Chemosphere 50 (10), 1319–1330.  
492 [https://doi.org/10.1016/S0045-6535\(02\)00769-5](https://doi.org/10.1016/S0045-6535(02)00769-5)
- 493 6. Ankley, G.T., Brooks, B.W., Huggett, D.B., Sumpter, J.P., 2007. Repeating history:  
494 pharmaceuticals in the environment. Environ. Sci. Technol. 41, 8211-8217.  
495 <https://doi.org/10.1021/es072658j>
- 496 7. Beyer, J., Green, N.W., Brooks, S., Allan, I.J., Ruus, A., Gomes, T., Bråte, I.L.N., Schøyen,  
497 M. 2017. Blue mussels (*Mytilus edulis* spp.) as sentinel organisms in coastal pollution  
498 monitoring: A review. Mar. Environ. Res. 130, 338-365  
499 <https://doi.org/10.1016/j.marenvres.2017.07.024>
- 500 8. Bocchetti, R., Regoli, F., 2006. Seasonal variability of oxidative biomarkers, lysosomal  
501 parameters, metallothioneins and peroxisomal enzymes in the Mediterranean mussel *Mytilus*  
502 *galloprovincialis* from Adriatic Sea. Chemosphere 65: 913-921.  
503 <https://doi.org/10.1016/j.chemosphere.2006.03.049>
- 504 9. Bonnefille, B., Gomez, E., Courant, F., Escande, A., Fenet, H. 2018. Diclofenac in the marine  
505 environment: A review of its occurrence and effects. Mar. Pollut. Bull. 131, 496-506.  
506 <https://doi.org/10.1016/j.marpolbul.2018.04.053>

- 507 10. Bu, Q., Shi, X., Yu, G., Huang, J., Wang, B., 2016. Assessing the persistence of  
508 pharmaceuticals in the aquatic environment: challenges and needs. *Emerg. Contam.* 2 (3),  
509 145–147. <https://doi.org/10.1016/j.emcon.2016.05.003>
- 510 11. Boxall, A.B., Rudd, M.A., Brooks, B.W., Caldwell, D.J., et al. 2012. Pharmaceuticals and  
511 personal care products in the environment: what are the big questions? *Environ. Health*  
512 *Perspect.* 120, 1221e1229. <https://doi.org/10.1289/ehp.1104477>
- 513 12. Burket, S.R., White, M., Ramirez, A.J., Stanley, J.K., Banks, K.E., Waller, W.T., Chambliss,  
514 C.K., Brooks, B.W., 2019. *Corbicula fluminea* rapidly accumulate pharmaceuticals in an  
515 effluent dependent urban stream. *Chemosphere* 224, 873-883.  
516 <https://doi.org/10.1016/j.chemosphere.2019.03.014>
- 517 13. Caban, M., Szaniawska, A., Stepnowski, P. 2016. Screening of 17 $\alpha$ -ethynylestradiol and non-  
518 steroidal anti-inflammatory pharmaceuticals accumulation in *Mytilus edulis trossulus* (Gould,  
519 1890) collected from the Gulf of Gdańsk, *Oceanol. Hydrobiol. Stud.* 45 605–614.  
520 <https://doi.org/10.1515/ohs-2016-0050>.
- 521 14. Calisto, V., Bahlmann, A., Schneider, R.J., Esteves, V.I., 2011. Application of an ELISA to  
522 the quantification of carbamazepine in ground, surface and wastewaters and validation with  
523 LC-MS/MS. *Chemosphere* 84, 1708–1715.  
524 <https://doi.org/10.1016/j.chemosphere.2011.04.072>
- 525 15. Canesi, L., Lorusso, L.C., Ciacci, C., Betti, M., Regoli, F., Poiana, G., Gallo, G., Marcomini,  
526 A., 2007. Effects of blood lipid lowering pharmaceuticals (bezafibrate and gemfibrozil) on  
527 immune and digestive gland functions of the bivalve mollusc, *Mytilus galloprovincialis*.  
528 *Chemosphere* 69, 994-1002. <https://doi.org/10.1016/j.chemosphere.2007.04.085>
- 529 16. Capolupo, M., Franzellitti, S., Kiwan, A., Valbonesi, P., Dinelli, E., Pignotti, E., Birke, M.,  
530 Fabbri, E., 2017. A comprehensive evaluation of the environmental quality of a coastal lagoon  
531 (Ravenna, Italy): integrating chemical and physiological analyses in mussels as a

- 532 biomonitoring strategy. *Sci. Total Environ.* 598, 146-159.  
533 <https://doi.org/10.1016/j.scitotenv.2017.04.119>.
- 534 17. Clarke, K..R., Gorley, R.N., 2001. PRIMER v5: User Manual/Tutorial. PRIMER-E,  
535 Plymouth.
- 536 18. Coll, M., Piroddi, C., Albouy, C., Rais Lasram, F.B., Cheung, W.W.L., Christensen, V.,  
537 Karpouzi, V.S., Guilhaumon, F., Mouillot, D., Paleczny, M., Palomares, M.L., Steenbeek, J.,  
538 Trujillo, P., Watson, R., Pauly, D., 2012. The Mediterranean Sea under siege: spatial overlap  
539 between marine biodiversity, cumulative threats and marine reserves. *Global Ecol. Biogeogr*  
540 21, 465–480. <https://doi.org/10.1111/j.1466-8238.2011.00697.x>
- 541 19. Commission Implementing Decision (EU) 2018/840 of 5 June 2018 establishing a watch list  
542 of substances for Union-wide monitoring in the field of water policy pursuant to Directive  
543 2008/105/EC of the European Parliament and of the Council and repealing Commission  
544 Implementing Decision (EU) 2015/495 (notified under document C (2018) 3362)
- 545 20. Communication from the Commission to the European Parliament, the Council and the  
546 European Economic and Social Committee. European Union Strategic Approach to  
547 Pharmaceuticals in the Environment COM/2019/128 final
- 548 21. Cui, Y., Balshaw, D.M., Kwok, R.K., Thompson, C.L., Collman, G.W., Birnbaum, L.S., 2016.  
549 The exposome: embracing the complexity for discovery in environmental health. *Environ.*  
550 *Health Perspect.* 124, A137–A140. <https://doi.org/10.1289/EHP412>
- 551 22. Cunha, S.C., Pena, A., Fernandes, J.O., 2017. Mussels as bioindicators of diclofenac  
552 contamination in coastal environments. *Environ. Pollut.* 225, 354–360.  
553 <https://doi.org/10.1016/j.envpol.2017.02.061>
- 554 23. de Solla, S.R., Gilroy, È.A.M., Klinck, J.S., King, L.E., McInnis, R., Struger, J., Backus, S.M.,  
555 Gillis, P.L., 2016. Bioaccumulation of pharmaceuticals and personal care products in the  
556 unionid mussel *Lasmigona costata* in a river receiving wastewater effluent. *Chemosphere* 146,  
557 486–496. <https://doi.org/10.1016/j.chemosphere.2015.12.022>

- 558 24. Desbiolles, F., Malleret, L., Tiliacos, C., Wong-Wah-Chung, P., Laffont-Schwob, I., 2018.  
559 Occurrence and ecotoxicological assessment of pharmaceuticals: is there a risk for the  
560 Mediterranean aquatic environment? *Sci. Total Environ.* 639, 1334–1348.  
561 <https://doi.org/10.1016/j.scitotenv.2018.04.351>
- 562 25. Ding, J., Lu, G., Li, Y., 2016. Interactive effects of selected pharmaceutical mixtures on  
563 bioaccumulation and biochemical status in crucian carp (*Carassius auratus*). *Chemosphere*  
564 148, 21–31. <https://doi.org/10.1016/j.chemosphere.2016.01.017>
- 565 26. Dodder, N.G., Maruya, K.A., Lee Ferguson, P., Grace, R., Klosterhaus, S., La Guardia, M.J.,  
566 Lauenstein, G.G., Ramirez, J., 2014. Occurrence of contaminants of emerging concern in  
567 mussels (*Mytilus spp.*) along the California coast and the influence of land use, storm water  
568 discharge, and treated wastewater effluent. *Mar. Pollut. Bull.* 81(2): 340-6.  
569 <https://doi.org/10.1016/j.marpolbul.2013.06.041>
- 570 27. Du, B., Haddad, S.P., Luek, A., Scott, W.C., Saari, G.N., Kristofco, L.A., Connors, K.A.,  
571 Rash, C., Rasmussen, J.B., Chambliss, C.K., Brooks, B.W., 2014. Bioaccumulation and  
572 trophic dilution of human pharmaceuticals across trophic positions of an effluent-dependent  
573 wadeable stream. *Phil. Trans. R. Soc. B* 369. <https://doi.org/10.1098/rstb.2014.0058>
- 574 28. Ebele, A.J., Abou-Elwafa Abdallah, M., Harrad, S., 2017. Pharmaceuticals and personal care  
575 products (PPCPs) in the freshwater aquatic environment. *Emerg. Contam.* 3, 1–16.  
576 <https://doi.org/10.1016/j.emcon.2016.12.004>
- 577 29. Erzinger, G.S., Pinto, L. H., Del Ciampo, L.F., Schulter, L. S., Sierth, R. S., Teixeira, M.C.  
578 F., Biff, H., Pezzini, B. R. 2013 Emerging pollutants: environmental impact of disposal of  
579 drugs. ISEE Conference Abstracts, Volume 2013, Issue 1 (2013).
- 580 30. Faccini, M., Leone, R., Pajusco, B., Quaglio, G., Casari, R., Albiero, A., Donati, M.,  
581 Lugoboni, F., 2012. Lormetazepam addiction. Data analysis from an Italian medical unit for  
582 addiction. *Risk Manag. Healthc. Policy* 5, 43–48. <https://doi.org/10.2147/RMHP.S31745>

- 583 31. Fabbri, E., Franzellitti, S., 2016. Human pharmaceuticals in the marine environment: focus  
584 on exposure and biological effects in animal species. *Environ. Toxicol. Chem.* 35, 799-812.  
585 <https://doi.org/10.1002/etc.3131>
- 586 32. Fattorini, D., Notti, A., Di Mento, R., Cicero, A.M., Gabellini, M., Russo, A., Regoli, F., 2008.  
587 Seasonal and inter-annual variations of trace metals in mussels from the Adriatic Sea: a  
588 regional gradient for arsenic and implications for monitoring the impact of off-shore activities.  
589 *Chemosphere* 72, 1524-1533. <https://doi.org/10.1016/j.chemosphere.2008.04.071>
- 590 33. Freitas, R., Almeida, A., Calisto, V., Velez, C., Moreira, A., Schneider, R.J., Esteves,  
591 V.I., Wrona, F.J., Figueira, E., Soares, A.M.V.M., 2016. The impacts of pharmaceutical drugs  
592 under ocean acidification: new data on single and combined long-term effects of  
593 carbamazepine on *Scrobicularia plana*. *Sci. Total Environ.* 541, 977–985.  
594 <https://doi.org/10.1016/j.scitotenv.2015.09.138>
- 595 34. Giuliani, M.E., Benedetti, M., Arukwe, A., Regoli, F., 2013. Transcriptional and catalytic  
596 responses of antioxidant and biotransformation pathways in mussels, *Mytilus*  
597 *galloprovincialis*, exposed to chemical mixtures. *Aquat. Toxicol.* 134–135: 120–127.  
598 <https://doi.org/10.1016/j.aquatox.2013.03.012>
- 599 35. Godoy, A. A., de Oliveira, A. C., Silva, J. G. M., de Jesus Azevedo, C. C., Domingues, I.,  
600 Nogueira, A. J. A., Kummrow, F. 2019. Single and mixture toxicity of four pharmaceuticals  
601 of environmental concern to aquatic organisms, including a behavioral assessment.  
602 *Chemosphere* 235, 373-382. <https://doi.org/10.1016/j.chemosphere.2019.06.200>
- 603 36. Gonzalez-Rey, M., Tapie, N., Le Menach, K., Dévier, M.-H., Budzinski, H., Bebianno, M.J.  
604 2015. Occurrence of pharmaceutical compounds and pesticides in aquatic systems. *Mar.*  
605 *Pollut. Bull.* 96, 384-400  
606 <https://doi.org/10.1016/j.marpolbul.2015.04.029>
- 607 37. Grabicova, K., Grabic, R., Blaha, M., Kumar, V., Cerveny, D., Fedorova, G., Randak, T.,  
608 2015. Presence of pharmaceuticals in benthic fauna living in a small stream affected by

- 609 effluent from a municipal sewage treatment plant. *Water Res.* 72, 145–153.  
610 <https://doi.org/10.1016/j.watres.2014.09.018>
- 611 38. Gros, M., Rodríguez-Mozaz, S., Barceló, D., 2012. Fast and comprehensive multi-residue  
612 analysis of a broad range of human and veterinary pharmaceuticals and some of their  
613 metabolites in surface and treated waters by ultra-high-performance liquid chromatography  
614 coupled to quadrupole-linear ion trap tandem. *J. Chromatogr. A* 1248, 104–121.  
615 <https://doi.org/10.1016/j.chroma.2012.05.084>
- 616 39. Hernando M.D., Mezcua M., Fernandez-Alba A.R., Barceló D. 2006. Environmental risk  
617 assessment of pharmaceutical residues in wastewater effluents, surface waters and sediments.  
618 *Talanta*; 69:334–42. <https://doi.org/10.1016/j.talanta.2005.09.037>
- 619 40. Huerta, Rodríguez-Mozaz, S., Barceló, D. 2012. Pharmaceuticals in biota in the aquatic  
620 environment: analytical methods and environmental implications. *Anal Bioanal Chem* (2012)  
621 404:2611-2624. DOI 10.1007/s00216-012-6144-y
- 622 41. Kay, P., Hughes, S.R., Ault, J.R., Ashcroft, A.E., Brown, L.E., 2017. Widespread, routine  
623 occurrence of pharmaceuticals in sewage effluent, combined sewer overflows and receiving  
624 waters. *Environ. Pollut.* 220, 1447–1455. <https://doi.org/10.1016/j.envpol.2016.10.087>
- 625 42. Klosterhaus, S.L., Grace, R., Hamilton, M.C., Yee, D., 2013. Method validation and  
626 reconnaissance of pharmaceuticals, personal care products, and alkylphenols in surface  
627 waters, sediments, and mussels in an urban estuary. *Environ. Int.* 54, 92–99.  
628 <https://doi.org/10.1016/j.envint.2013.01.009>
- 629 43. Liu, J., Lu, G., Xie, Z., Zhang, Z., Li, S., Yan, Z., 2015. Occurrence, bioaccumulation and  
630 risk assessment of lipophilic pharmaceutically active compounds in the downstream rivers of  
631 sewage treatment plants. *Sci. Total Environ.* 511, 54–62.  
632 <https://doi.org/10.1016/j.scitotenv.2014.12.033>
- 633 44. Martínez Bueno, M.J., Boillot, C., Fenet, H., Chiron, S., Casellas, C., Gómez, E., 2013. Fast  
634 and easy extraction combined with high resolution-mass spectrometry for residue analysis of

- 635 two anticonvulsants and their transformation products in marine mussels. *J. Chromatogr. A*  
636 1305, 27–34. <https://doi.org/10.1016/j.chroma.2013.06.071>
- 637 45. Martinez Bueno, M.J.M., Boillot, C., Munaron, D., Fenet, H., Casellas, C., Gomez, E., 2014.  
638 Occurrence of venlafaxine residues and its metabolites in marine mussels at trace levels:  
639 development of analytical method and a monitoring program. *Anal. Bioanal. Chem.* 406, 601–  
640 610. <https://doi.org/10.1007/s00216-013-7477-x>
- 641 46. Martínez-Morcillo, S., Rodríguez-Gil, J.L., Fernández-Rubio, J., Rodríguez-Mozaz, S., María  
642 Prado Míguez-Santiyán, M.P., Valdese, M.E., Barceló, D., Valcárcel, Y. 2020. Presence of  
643 pharmaceutical compounds, levels of biochemical biomarkers in seafood tissues and risk  
644 assessment for human health: Results from a case study in North-Western Spain. *Int. J. Hyg.*  
645 *Environ. Heal.* 223, 10-21. <https://doi.org/10.1016/j.ijheh.2019.10.011>
- 646 47. Maruya K., Dodder, N.G., Tang, C-L, Lao, W., Tsukada, D. 2014. Which coastal and marine  
647 environmental contaminants are truly emerging? *Environ Sci Pollut Res.* DOI  
648 [10.1007/s11356-014-2856-1](https://doi.org/10.1007/s11356-014-2856-1)
- 649 48. McEneff, G., Barron, L., Kelleher, B., Paull, B., Quinn, B., 2014. A year-long study of the  
650 spatial occurrence and relative distribution of pharmaceutical residues in sewage effluent,  
651 receiving marine waters and marine bivalves. *Sci. Total Environ.* 476–477, 317–326.  
652 <https://doi.org/10.1016/j.scitotenv.2013.12.123>
- 653 49. Mendoza, A., Rodríguez-Gil, J.L., González-Alonso, S., Mastroianni, N., Lopez de Alda, M.,  
654 Barcelò, D., Valcarcel, Y., 2014. Drugs of abuse and benzodiazepines in the Madrid Region  
655 (Central Spain): seasonal variation in river waters, occurrence in tap water and potential  
656 environmental and human risk. *Environ. Int.* 70, 76–87.  
657 <https://doi.org/10.1016/j.envint.2014.05.009>
- 658 50. Mezzelani, M., Gorbi, S., Da Ros, Z., Fattorini, D., d'Errico, G., Milan, M., Bargelloni, L.,  
659 Regoli, F., 2016a. Ecotoxicological potential of Non-Steroidal Anti-Inflammatory Drugs  
660 (NSAIDs) in marine organisms: bioavailability, biomarkers and natural occurrence in *Mytilus*

- 661 *galloprovincialis*. Mar. Environ. Res. 121, 31–39.  
662 <https://doi.org/10.1016/j.marenvres.2016.03.005>
- 663 51. Mezzelani, M., Gorbi, S., Fattorini, D., d'Errico, G., Benedetti, M., Milan, M., Bargelloni, L.,  
664 Regoli, F., 2016b. Transcriptional and cellular effects of non-Steroidal Anti-inflammatory  
665 drugs (NSAIDs) in experimentally exposed mussels, *Mytilus galloprovincialis*. Aquat.  
666 Toxicol. 180, 306–313. <https://doi.org/10.1016/j.aquatox.2016.10.006>
- 667 52. Mezzelani, M., Gorbi, S., Regoli, F., 2018a. Pharmaceuticals in the aquatic environments:  
668 evidence of emerged threat and future challenges for marine organisms. Mar. Environ. Res.  
669 140, 41–60. <https://doi.org/10.1016/J.MARENVRES.2018.05.001>.
- 670 53. Mezzelani, M., Gorbi, S., Fattorini, D., d'Errico, G., Consolandi, G., Milan, M., Bargelloni,  
671 L., Regoli, F., 2018b. Long-term exposure of *Mytilus galloprovincialis* to Diclofenac,  
672 Ibuprofen and Ketoprofen: insights into bioavailability, biomarkers and transcriptomic  
673 changes. Chemosphere 198, 238–248. <https://doi.org/10.1016/j.chemosphere.2018.01.148>
- 674 54. Miller, T.H., Bury, N.R., Owen, S.F., MacRae, J.I., Barron. L.P. 2018. A review of the  
675 pharmaceutical exposome in aquatic fauna. Environ. Pollut. 239, 129–146.  
676 <https://doi.org/10.1016/j.envpol.2018.04.012>
- 677 55. Miller, T.H., Ng, K.T., Bury, S.T., Bury, N.R., Barron. L.P., 2019. Biomonitoring of  
678 pesticides, pharmaceuticals and illicit drugs in a freshwater invertebrate to estimate toxic or  
679 effect pressure. Environ. Int. 129, 595–606 <https://doi.org/10.1016/j.envint.2019.04.038>
- 680 56. Mijangos, L., Ziarrusta, H., Ros, O., Kortazar, L., Fern\_andez, L.A., Olivares, M., Zuloaga,  
681 O., Prieto, A., Etxebarria, N., 2018. Occurrence of emerging pollutants in estuaries of the  
682 Basque Country: analysis of sources and distribution, and assessment of the environmental  
683 risk. Water Res. 147, 152–163.
- 684 57. Mole, R. A.; Brooks, B. W. 2019. Global scanning of selective serotonin reuptake inhibitors:  
685 occurrence, wastewater treatment and hazards in aquatic systems. Environ. Pollut. 250, 1019–  
686 1031. <https://doi.org/10.1016/j.envpol.2019.04.118>

- 687 58. Moreno-González, R., Rodríguez-Mozaz, S., Gros, M., Barceló, D., León, V.M., 2015.  
688 Seasonal distribution of pharmaceuticals in marine water and sediment from a Mediterranean  
689 coastal lagoon (SE Spain). *Environ. Res.* 138, 326–344.  
690 <https://doi.org/10.1016/j.envres.2015.02.016>
- 691 59. Moreno-González, R., Rodríguez-Mozaz, S., Huerta, B., Barceló, D., León, V.M., 2016. Do  
692 pharmaceuticals bioaccumulate in marine molluscs and fish from a coastal lagoon? *Environ.*  
693 *Res.* 146, 282–298. <https://doi.org/10.1016/j.envres.2016.01.001>
- 694 60. Oaks, J.L., Gilbert, M., Virani, M.Z., Watson, R.T., Meteyer, C.U., Rideout, B.A.,  
695 Shivaprasad, H.L., Ahmed, S., Chaudhry, M.J.I., Arshad, M., Mahmood, S., Ali, A., Khan,  
696 A.A., 2004. Diclofenac residues as the cause of vulture population decline in Pakistan. *Nature*  
697 427 (6975), 630–633. <https://doi.org/10.1038/nature02317>
- 698 61. Oksanen, J., Blanchet, F.G., Kindt, R., Legendre, P., Minchin, P.R., O’Hara, R.B., Simpson,  
699 G.L., Solymos, P., Henry, M., Stevens, H., Wagner, H., 2011. *Vegan: Community Ecology.*  
700 *Package. R Package Version 2.0-2.* <<http://CRAN.R-project.org/package=vegan>>.
- 701 62. Oliveira, P., Almeida, A., Calisto, V., Esteves, V.I., Schneider, R.J., Wrona, F.J., Soares, A.  
702 M. V. M., Figueira, E., Freitas, R. 2017. Physiological and biochemical alterations induced in  
703 the mussel *Mytilus galloprovincialis* after short and long-term exposure to carbamazepine.  
704 *Water Res.* 117, 102–114. <https://doi.org/10.1016/j.watres.2017.03.052>
- 705 63. OsMed, Osservatorio Nazionale sull’impiego dei Medicinali. L’uso dei farmaci in Italia.  
706 Rapporto Nazionale 2017 dell’Osservatorio Nazionale sull’impiego dei Medicinali (OsMed).  
707 The Medicines Utilisation Monitoring Centre. National Report on Medicines use in Italy. Year  
708 2017. Rome: Italian Medicines Agency, 2018.
- 709 64. Peake, B.M., Braund, R., Tong, A.Y.C., Tremblay, L.A., 2016. The Life-cycle of  
710 Pharmaceuticals in the Environment. Woodhead Publishing Series in Biomedicine, Number  
711 51

- 712 65. Pereira, A.M.P.T., Silva, L.J.G., Meisel, L.M., Lino, C.M., Pena, A., 2015. Environmental  
713 impact of pharmaceuticals from Portuguese wastewaters: geographical and seasonal  
714 occurrence, removal and risk assessment. *Environ. Res.* 136, 108–119.  
715 <https://doi.org/10.1016/j.envres.2014.09.041>
- 716 66. Pisanelli, B., Benedetti, M., Fattorini, D., Regoli, F., 2009. Seasonal and inter-annual  
717 variability of DNA integrity in mussels *Mytilus galloprovincialis*: a possible role for natural  
718 fluctuations of trace metal concentrations and oxidative biomarkers. *Chemosphere* 77, 1551–  
719 1557. <https://doi.org/10.1016/j.chemosphere.2009.09.048>
- 720 67. Regoli, F., D’Errico, G., Nardi, A., Mezzelani, M., Fattorini, D., Benedetti, M., Di Carlo, M.,  
721 Pellegrini, D., Gorbi, S. 2019. application of a Weight Of Evidence approach for monitoring  
722 complex environmental scenarios: the case-study of off-shore platforms. *Frontiers in Marine*  
723 *Science* 6, 377. <https://doi.org/10.3389/fmars.2019.00377>
- 724 68. Regoli, F., Pellegrini, D., Cicero, A.M., Nigro, N., Benedetti, M., Gorbi, S., Fattorini, D.,  
725 D’Errico, G., Di Carlo, M., Nardi, A., Gaion, A., Scuderi, A., Giuliani, S., Romanelli, G.,  
726 Berto, D., Trabucco, B., Guidi, P., Bernardeschi, M., Scarcella, V., Frenzilli, G., 2014. A  
727 multidisciplinary weight of evidence approach for environmental risk assessment at the Costa  
728 Concordia wreck: integrative indices from Mussel Watch. *Mar. Environ. Res.* 96, 92-104.  
729 <https://doi.org/10.1016/j.marenvres.2013.09.016>
- 730 69. Serra-Compte, A.; Álvarez-Muñoz, D.; Rodríguez-Mozaz, S.; Barcelo, D. Multi-residue  
731 method for the determination of antibiotics and some of their metabolites in seafood. *Food*  
732 *Chem. Toxicol.* 2017, 104, 3–13. <https://doi.org/10.1021/acs.estlett.9b00112>
- 733 70. Salgado, R., Marques, R., Noronha, J.P., Mexia, J.T., Carvalho, G., Oehmen, A., Reis, M.M.,  
734 2011. Assessing the diurnal variability of pharmaceutical and personal care products in a full-  
735 scale activated sludge plant. *Environ. Pollut.* 159, 2359-2367.  
736 <https://doi.org/10.1016/j.envpol.2011.07.004>

- 737 71. Suaria, G., Avio, C.G., Mineo, A., Lattin, G.L., Magaldi, M.G., Belmonte, G., Moore, C.J.,  
738 Regoli, F., Aliani, S., 2016. The Mediterranean plastic soup: synthetic polymers in  
739 Mediterranean surface waters. *Sci. Rep.* 6, 37551. <https://doi.org/10.1038/srep375512016>
- 740 72. Swiacka, K., Maculewicz, J., Smolarz, K., Szaniawska, A., Caban, M. 2019. Mytilidae as  
741 model organisms in the marine ecotoxicology of pharmaceuticals - A review. *Environmental*  
742 *Pollution* 254, article 113082. <https://doi.org/10.1016/j.envpol.2019.113082>
- 743 73. Trombini, C., Hampel, M., Blasco, J. 2019. Assessing the effect of human pharmaceuticals  
744 (carbamazepine, diclofenac and ibuprofen) on the marine clam *Ruditapes philippinarum*: An  
745 integrative and multibiomarker approach. *Aquat. Toxicol.* 208, 146-156  
746 <https://doi.org/10.1016/j.aquatox.2019.01.004>
- 747 74. Väitalo, P., Kruglova, A., Mikola, A., Vahala, R., 2017. Toxicological impacts of antibiotics  
748 on aquatic micro-organisms: a mini-review. *Int. J. Hyg Environ. Health* 220, 558–569.  
749 <https://doi.org/10.1016/j.ijheh.2017.02.003>
- 750 75. Wille, K., Kiebooms, J.L., Claessens, M., Rappé, K., Vanden Bussche, J., Noppe, H., Van  
751 Praet, N., De Wulf, E., Van Caeter, P., Janssen, C.R., De Brabander, H.F., Vanhaecke, L.,  
752 2011. Development of analytical strategies using U-HPLC-MS/MS and LC-ToF-MS for the  
753 quantification of micropollutants in marine organisms. *Anal. Bioanal. Chem.* 400, 1459–1472.  
754 <https://doi.org/10.1007/s00216-011-4878-6>
- 755 76. Wolecki, D., Caban, M., Pazdro, K., Mulkiewicz, E., Stepnowski, P., Kumirska, J. 2019.  
756 Simultaneous determination of non-steroidal anti-inflammatory drugs and natural estrogens  
757 in the mussels *Mytilus edulis trossulus*. *Talanta.* 200, 316-323.  
758 <https://doi.org/10.1016/j.talanta.2019.03.062>
- 759 77. Xie, Z., Lu, G., Yan, Z., Liu, J., Wang, P., Wang, Y., 2017. Bioaccumulation and trophic  
760 transfer of pharmaceuticals in food webs from a large freshwater lake. *Environ. Pollut.* 222,  
761 356–366. <https://doi.org/10.1016/j.envpol.2016.12.026>

- 762 78. Zhu, S., Dong, B., Wu, Y., Buc, L., Zhou, S. 2019. Degradation of carbamazepine by vacuum-  
763 UV oxidation process: kinetics modeling and energy efficiency, *J. Hazard. Mater.* 368 178–  
764 185. <https://doi.org/10.1016/j.jhazmat.2019.01.043>
- 765 79. Zou, H., Radke, M., Kierkegaard, A., MacLeod, M., McLachlan, M.S., 2015. Using chemical  
766 benchmarking to determine the persistence of chemicals in a Swedish lake. *Environ. Sci.*  
767 *Technol.* 49 (3), 1646–1653. <https://doi.org/10.1021/es505548k>

**Table 1.** Concentrations of pharmaceuticals in the whole tissues of *M. galloprovincialis* collected in Senigallia (S1), Torrette (S2) and Portonovo (S3) from 2014 to 2017. Data are given as mean values  $\pm$  standard deviations (n=5). NSAIDs: Non Steroidal Anti-Inflammatory Drugs; PSY: psychiatric drugs; AH: antihypertensive drug; DIC: diclofenac; IBU: ibuprofen; NIM: nimesulide;  $\Sigma$  NSAIDs: Total NSAIDs (sum of DIC, IBU and NIM); CBZ: carbamazepine; PAR: paroxetine; LOR: Lormetazepam;  $\Sigma$ PSY: Total PSY (sum of CBZ, PAR and LOR); VAL: valsartan; n.a. not analyzed. Values are expressed as ng/g dw for all the individual drugs while  $\Sigma$ NSAIDs and  $\Sigma$ PSY are expressed as nmol/g to normalize different molecular weights of different compounds. *p* values are reported and letters indicate significant differences between groups of means (whithin each site and for each molecule) (Newman Keuls post hoc); n.s. not statistically significant; n.t. not tested.

Site	Year	Season	Month	NSAIDs				PSY				AH	
				DIC ng g <sup>-1</sup> (d.w.)	IBU ng g <sup>-1</sup> (d.w.)	NIM ng g <sup>-1</sup> (d.w.)	$\Sigma$ NSAIDs nmol g <sup>-1</sup> (d.w.)	CBZ ng g <sup>-1</sup> (d.w.)	PAR ng g <sup>-1</sup> (d.w.)	LOR ng g <sup>-1</sup> (d.w.)	$\Sigma$ PSY nmol g <sup>-1</sup> (d.w.)	VAL ng g <sup>-1</sup> (d.w.)	
S1	2014	Summer	Jul	<1.4	<8.0	2.3 $\pm$ 2.2	0.01 $\pm$ 0.02 (a)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
			Aug	1.4 $\pm$ 0.8 (a)	<8.0	2.2 $\pm$ 1.0	0.03 $\pm$ 0.00 (ab)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
	2015	Summer	Jul	103.8 $\pm$ 27.9 (b)	<8.0	<2.0	0.35 $\pm$ 0.09 (ab)	45.5 $\pm$ 14.7 (b)	16.7 $\pm$ 8.8 (b)	6.4 $\pm$ 8.5	0.26 $\pm$ 0.07 (b)	1.2 $\pm$ 2.0 (a)	
			Aug	<1.4	<8.0	<2.0	<0.0044	151.1 $\pm$ 27.9 (c)	9.1 $\pm$ 4.5 (ab)	<0.4	0.66 $\pm$ 0.11 (c)	3.2 $\pm$ 1.2 (b)	
	2016	Summer	Jul	103.8 $\pm$ 27.9 (b)	<8.0	<2.0	0.35 $\pm$ 0.09 (ab)	45.5 $\pm$ 14.7 (b)	16.7 $\pm$ 8.8 (b)	6.4 $\pm$ 8.5	0.26 $\pm$ 0.07 (b)	1.2 $\pm$ 2.0 (a)	
			Aug	<1.4	<8.0	<2.0	<0.0044	151.1 $\pm$ 27.9 (c)	9.1 $\pm$ 4.5 (ab)	<0.4	0.66 $\pm$ 0.11 (c)	3.2 $\pm$ 1.2 (b)	
	2017	Summer	Jul	103.8 $\pm$ 27.9 (b)	<8.0	<2.0	0.35 $\pm$ 0.09 (ab)	45.5 $\pm$ 14.7 (b)	16.7 $\pm$ 8.8 (b)	6.4 $\pm$ 8.5	0.26 $\pm$ 0.07 (b)	1.2 $\pm$ 2.0 (a)	
			Aug	<1.4	<8.0	<2.0	<0.0044	151.1 $\pm$ 27.9 (c)	9.1 $\pm$ 4.5 (ab)	<0.4	0.66 $\pm$ 0.11 (c)	3.2 $\pm$ 1.2 (b)	
	2015	Spring	Apr	29.6 $\pm$ 10.2 (b)	143.7 $\pm$ 242.0	<2.0	0.12 $\pm$ 0.03 (ab)	n.a.	n.a.	n.a.	n.a.	n.a.	
			Jul	103.8 $\pm$ 27.9 (b)	<8.0	<2.0	0.35 $\pm$ 0.09 (ab)	45.5 $\pm$ 14.7 (b)	16.7 $\pm$ 8.8 (b)	6.4 $\pm$ 8.5	0.26 $\pm$ 0.07 (b)	1.2 $\pm$ 2.0 (a)	
	2016	Spring	May	99.1 $\pm$ 24.0 (b)	<8.0	<2.0	0.33 $\pm$ 0.08 (b)	270.5 $\pm$ 107.4 (d)	1.6 $\pm$ 2.6 (a)	<0.4	1.15 $\pm$ 0.45 (d)	<0.5	
			Jul	2.5 $\pm$ 2.5 (a)	<8.0	<2.0	0.02 $\pm$ 0.02 (a)	32.7 $\pm$ 9.0 (ab)	30.0 $\pm$ 17.0 (b)	<0.4	0.22 $\pm$ 0.08 (b)	0.9 $\pm$ 0.8 (a)	
	2017	Spring	May	109.3 $\pm$ 50.7 (b)	<8.0	<2.0	0.37 $\pm$ 0.16 (b)	139.4 $\pm$ 57.8 (c)	5.3 $\pm$ 1.1 (ab)	<0.4	0.61 $\pm$ 0.24 (c)	1.5 $\pm$ 1.4 (a)	
			Jul	<1.4	<8.0	<2.0	<0.0044	21.9 $\pm$ 6.5 (a)	3.4 $\pm$ 5.4 (ab)	2.4 $\pm$ 3.1	0.11 $\pm$ 0.03 (a)	0.5 $\pm$ 0.4 (a)	
Sig.			<i>p</i> < 0.001	(n.t.)	(n.t.)	<i>p</i> < 0.001	<i>p</i> < 0.001	<i>p</i> < 0.01	(n.t.)	<i>p</i> < 0.001			
S2	2014	Summer	Jul	<1.4	<8.0 (n.t.)	56.0	0.2	n.a.	n.a.	n.a.	n.a.	n.a.	
			Aug	1.7 $\pm$ 1.2	13.6 $\pm$ 10.6	5.8 $\pm$ 6.8	0.09 $\pm$ 0.04	n.a.	n.a.	n.a.	n.a.	n.a.	
	2015	Summer	Jul	20.6 $\pm$ 27.3	<8.0	<2.0	0.07 $\pm$ 0.10	62.9 $\pm$ 7.7 (b)	2.7 $\pm$ 2.1	1.4 $\pm$ 1.6	0.28 $\pm$ 0.03 (bc)	1.3 $\pm$ 0.8 (b)	
			Aug	<1.4	<8.0	61.0 $\pm$ 134.0	0.22 $\pm$ 0.43	34.6 $\pm$ 25.8 (a)	7.0 $\pm$ 5.7	18.9 $\pm$ 25.1	0.22 $\pm$ 0.15 (bc)	<0.5	
	2016	Spring	May	36.4 $\pm$ 35.1	<8.0	3.7 $\pm$ 4.0	0.14 $\pm$ 0.11	<1.0	<1.0	104.8 $\pm$ 105.9	0.31 $\pm$ 0.32 (b)	1.3 $\pm$ 1.1 (b)	
			Jul	14.0 $\pm$ 29.9	28.4 $\pm$ 19.7	<2.0	0.19 $\pm$ 0.07	<1.0	4.0 $\pm$ 5.3	<0.4	0.01 $\pm$ 0.01 (a)	1.8 $\pm$ 1.5 (b)	
	2017	Spring	May	6.5 $\pm$ 12.9	<8.0	<2.0	0.04 $\pm$ 0.04	216.8 $\pm$ 78.9 (b)	6.2 $\pm$ 4.0	2.2 $\pm$ 4.3	0.94 $\pm$ 0.34 (c)	<0.5	
			Jul	84.3 $\pm$ 82.1	<8.0	<2.0	0.29 $\pm$ 0.26	52.3 $\pm$ 31.4 (a)	1.0 $\pm$ 1.3	<0.4	0.22 $\pm$ 0.13 (bc)	0.4 $\pm$ 0.3 (a)	
	Sig.			(n.s.)	(n.t.)	(n.t.)	(n.s.)	<i>p</i> < 0.001	(n.s.)	(n.s.)	<i>p</i> < 0.001	<i>p</i> < 0.001	
	S3	2014	Summer	Jul	<1.4	<8.0 (n.t.)	6.7 $\pm$ 9.9 (n.t.)	0.04 $\pm$ 0.03	n.a.	n.a.	n.a.	n.a.	n.a.
				Aug	16.1 $\pm$ 14.7	9.4 $\pm$ 0.6	4.2 $\pm$ 2.5	0.11 $\pm$ 0.06	n.a.	n.a.	n.a.	n.a.	n.a.
		2015	Summer	Jul	171.1 $\pm$ 233.6	<8.0	<2.0	0.56 $\pm$ 0.73	76.1 $\pm$ 30.1	11.2 $\pm$ 7.8 (a)	2.2 $\pm$ 4.4	0.36 $\pm$ 0.14 (ab)	1.8 $\pm$ 1.6 (ab)
				Aug	52.1 $\pm$ 37.5	<8.0	<2.0	0.19 $\pm$ 0.12	74.4 $\pm$ 24.0 (ab)	2.3 $\pm$ 2.5 (a)	<0.40	0.32 $\pm$ 0.10 (ab)	<0.5
		2016	Spring	May	53.6 $\pm$ 31.4	<8.0	4.6 $\pm$ 7.9	0.20 $\pm$ 0.11	<1.0	6.7 $\pm$ 14.0 (a)	288.0 $\pm$ 130.7	0.88 $\pm$ 0.37 (b)	1.8 $\pm$ 0.7 (ab)
Jul				31.9 $\pm$ 32.9	<8.0	3.4 $\pm$ 3.8	0.13 $\pm$ 0.10	51.2 $\pm$ 46.4 (a)	<1.0	62.1 $\pm$ 138.4	0.40 $\pm$ 0.53 (b)	3.6 $\pm$ 0.6 (b)	
2017		Spring	May	16.8 $\pm$ 36.1	<8.0	<2.0	0.08 $\pm$ 0.11	128.7 $\pm$ 55.0 (b)	1.6 $\pm$ 1.6 (a)	<0.40	0.55 $\pm$ 0.23 (b)	<0.5	
			Jul	82.0 $\pm$ 27.2	<8.0	<2.0	0.28 $\pm$ 0.09	35.2 $\pm$ 14.2 (ab)	49.9 $\pm$ 22.2 (b)	<0.40	0.28 $\pm$ 0.09 (ab)	<0.5	
Sig.				n.s.	(n.t.)	(n.t.)	(n.s.)	<i>p</i> < 0.001	<i>p</i> < 0.001	(n.t.)	<i>p</i> < 0.001	<i>p</i> < 0.001	

## Legend of the Figures:

**Figure 1.** Map of sampling locations along the Tyrrhenian and Adriatic Sea.

**Figure 2.** nMDS analyses on bioaccumulation of DIC, IBU, NIM, CBZ, PAR, LOR and VAL, in *M. galloprovincialis* from Senigallia S1, Torrette S2, and Portonovo S3, sampled in different months and years. Different shapes indicate each site: “square” for S1; “triangle” for S2 and “circle” for S3, while different fillings indicate seasons: “white” for Autumn; “black” for Winter; “dotted” for Spring and “gray” for Summer. AMP and KET were always below detection limit and not elaborated.

**Figure 3.** Concentrations of Diclofenac, Ibuprofen, Nimesulide, Carbamazepine, Paroxetine, Lormetazepam, Total NSAIDs (sum of DIC, IBU and NIM), Total PSY (sum of CBZ, PAR and LOR) and Valsartan in the whole tissues of *M. galloprovincialis* collected in different sites along the Adriatic (S1-S8) and Tyrrhenian Sea (S9-S14). For sites sampled in more than one period, results are given as mean values  $\pm$  standard deviation of means concentrations measured in each sampling time; in all the other cases, results are given as mean values  $\pm$  standard deviation of replicates.

**Figure 4.** A) Detection frequency (% of analysed samples) of different pharmaceuticals in tissues of *M. galloprovincialis* from all sampling sites and periods B) Percentage of samples containing at least 1, 2, 3 or 4 pharmaceuticals.

Figure 1.




Figure 2.


















Figure 3.












**Figure 4.**











**A) DETECTION FREQUENCY (%)**



**B) n° MOLECULES/SAMPLES (%)**



### Declaration of interests

The authors (Marica Mezzelani, Daniele Fattorini, Stefania Gorbi, Marco Nigro, Francesco Regoli) declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Prof. Francesco Regoli, on behalf of all the authors.



## **CRedit author statement**

**Marica Mezzelani:** she participated to conceptualization of the study; she was responsible of data curation, formal analysis and original draft writing. **Daniele Fattorini:** he was responsible for analytical methods development, he participated to interpretation and data curation, formal analysis, review & editing. **Stefania Gorbi:** she participated to the conceptualization of the study, participated to the review of obtained results and editing of the manuscript. **Marco Nigro:** he participated to conceptualization of the study, discussion of results, support in sampling activities. **Francesco Regoli:** he participated to the conceptualization of the study and general supervision, funding acquisition, discussion of results and of manuscript structure, review and editing.

## SUPPLEMENTARY MATERIALS (SM)

### **Human pharmaceuticals in marine mussels: evidence of sneaky environmental hazard along Italian coasts**

Marica Mezzelani<sup>a</sup>, Daniele Fattorini<sup>a,b</sup>, Stefania Gorbi<sup>a,b</sup>, Marco Nigro<sup>c</sup>, Francesco Regoli<sup>a,b\*</sup>

<sup>a</sup> Dipartimento di Scienze della Vita e dell'Ambiente (DiSVA), Università Politecnica delle Marche, Ancona, Italy

<sup>b</sup> Consorzio Interuniversitario per le Scienze del Mare, CoNISMa, ULR Ancona, Ancona, Italy

<sup>c</sup> Dipartimento di Medicina Clinica e Sperimentale, Università di Pisa, Italy

\* Corresponding Author:

Prof. Francesco Regoli

Dipartimento di Scienze della Vita e dell'Ambiente (DiSVA),

Università Politecnica delle Marche,

via Breccie Bianche 60131, Ancona, Italy

e-mail: [f.regoli@univpm.it](mailto:f.regoli@univpm.it)

## Materials and Methods

### Sampling sites and periods

All the sampling locations and relative periods are indicated in Table SM1, which include the GPS coordinates and the main characteristics of the areas.

### Analytical methods for measurements of pharmaceuticals in mussels tissues.

Sample preparation and analytical measurements represent an update of previously reported methods (Mezzelani et al., 2016a, b; Mezzelani et al., 2018b). Protocols developed for the extraction, purification, separation and detection of AMP, DIC, IBU, KET and NIM were modified to include CBZ, LOR, PAR and VAL among pharmaceuticals detected in mussels tissues and the main applied HPLC conditions are summarized in the Table SM2.

HPLC grade methanol, acetonitrile and analytical standards (purity of  $\geq 97\%$ ) were purchased from Sigma Aldrich (Milan, Italy) for the following PhACs: Acetaminophen AMP (CAS 103-90-2), Carbamazepine CBZ (CAS 298-46-4) Diclofenac DIC (CAS 15307-86-5), Ibuprofen IBU (CAS 15687-27-1), Ketoprofen KET (CAS 22071-15-4) Lormetazepam LOR (CAS 848-75-9) Nimesulide NIM (CAS 51803-78-2), Paroxetine PAR (CAS 110429-35-1) and Valsartan VAL (CAS 137862-53-4). Stock solutions ( $1 \text{ mg mL}^{-1}$ ) were prepared every 5 days in methanol acidified at 0.1% with acetic acid in amber vials and stored at  $+4 \text{ }^\circ\text{C}$  in the dark to reduce possible degradation. Working solutions were prepared daily in methanol acidified at 0.1% with acetic acid.

Different homogenization and extraction buffers were used for various compounds: acetic acid 0.1%, pH = 3.26 (buffer 1) for CBZ, DIC, IBU, KET LOR, NIM, PAR and VAL, while ammonium phosphate 10 mM, pH = 4.0 with citric acid 100 mM (buffer 2) for AMP. About 3 g of wet tissues were homogenized in 5mL of buffer at room temperature for 20 minutes using a dispersing, stirring, homogenizing and grinding system (IKA ULTRA® TURRAX® Tube Drive). After centrifugation at  $4500 \times g$  for 30 minutes, samples were purified by Solid Phase Extraction (SPE) with reversed-phase tubes (Discovery DSC-18, 1g x 6 mL, Supelco, Bellefonte, Pennsylvania, USA). SPE tubes were conditioned with 6 mL of methanol, followed by 18 mL of ultra-pure water. Samples were diluted (1:1) with ultra-pure water and loaded onto the SPE cartridges; after washing with 12 mL of potassium bicarbonate  $\text{KHCO}_3$  and 6 mL of ultra-pure water, analytes were eluted and recovered using 2 mL of a solution constituted by methanol acidified at 0.1% with acetic acid (HPLC, gradient grade, Carlo Erba). The final conditions for the purification of the extracts with SPE techniques, including the type (C18) and mass (1g) of resin, the volume applied and recovered, are

the result of numerous tests conducted during the validation of the method, to guarantee the best extraction and purification yields. The C18 cartridges are widely used for the purification of environmental matrices. Obtained samples were filtered using Phenex<sup>TM</sup>-RC membrane (Regenerated Cellulose/Polypropylene 0.45  $\mu\text{m}$ , 15mm syringe filters, Phenomenex, US) and then centrifuged again at 12000  $\times\text{g}$  for 20 minutes.

Analytical detection of extracted PhACs was performed by High Performance Liquid Chromatography, with fluorimetric and diode array detectors DAD (Agilent Infinity 1260 series). Chromatographic separations of CBZ, DIC, IBU, KET, LOR, NIM, PAR and VAL were performed on a Kinetex column (C18, 5  $\mu\text{m}$ , 150 mm length, 4.6 mmID, Phenomenex, US), equipped with a security guard column (C18, 5  $\mu\text{m}$ , 4 mm length, 2.0 mmID, Phenomenex, US). For CBZ, DIC, KET and VAL a mobile phase composed by ultra-pure water (26%), acetonitrile (42%) and Buffer 1 (32%) was used under isocratic condition. Analyses of IBU, LOR, NIM and PAR were performed using ultra-pure water, acetonitrile, Buffer 1 gradient (from 35%:30%:35% to 0%:65%:35% linearly for 23 minutes). To guarantee the optimal resin cleaning condition, after each analyses a gradient was applied to linearly increase the organic phase content in the column (87.5%: 12.5% to 10%: 90%). During the validation phase mussel tissues (n=10) were homogenized, divided in two subsamples, one considered as Blank, while the other was spiked with various concentrations of standard solution of each tested compound. Spiked mussel samples were in contact with pharmaceuticals for 10 hours, before being analysed by HPLC. Both samples were injected in the HPLC to compare the spectra of Blank with those from the spiked sample: the chromatography was corrected to obtain the spectra in the cleaner field (i.e. area without interferences of other signals). Once obtained the best preliminary conditions, 20 samples (each constituted by 5 mussels), were tested to observe the variability of the background. When necessary, additional chromatography corrections have been tested to obtain the best conditions. After this, the optimal wavelengths were selected for each molecule (assuring at least 85% of the maximum absorbance) and the best qualifiers (with 50-75% of maximum absorbance) were identified. All wavelengths (main and qualifiers), have been repeatedly tested through the analyses of samples (mussels homogenates) spiked with known concentrations of standards, to verify linearity, dispersion of the points with respect to the calibration curve (n =10). These checks were further used to determine LOD/LOQ (Table SM3)

Following these procedures, DAD was used for monitoring the spectra from 190 nm to 350 nm, and the signal for CBZ, DIC, KET and LOR was obtained at 286 nm, 276 nm, 250 nm e 232 nm, respectively. NIM was detected using DAD from 190 nm to 410 nm and monitoring at 298 nm. Analytical detection of IBU, PAR and VAL was obtained by fluorimetric detector with excitation/emission wavelengths at 230/294 nm for IBU, 296/338 nm for PAR and 205/380 for VAL.

With such analytical conditions Limits of Detection (LOD) for individual pharmaceuticals were 0.60 ng for AMP, 0.82 ng for DIC, 4.80 ng IBU, 0.51 ng for KET, 1.26 ng for NIM, 0.62 ng for CBZ, 0.26 ng for LOR, 0.57 ng for PAR and 0.29 ng for VAL.

Separation of AMP was carried out by an Agilent Eclipse Plus column (C18, 3.5  $\mu$ m, 100 mm length, 4.6 mmID) with a security guard column (C18, 5  $\mu$ m, 4 mm length, 2.0 mmID, Phenomenex, US), and a mobile phase composed by Buffer 2 (87.5%) and methanol (12.5%) under isocratic condition; a fast, post-run gradient was applied to remove any unresolved compound retained by the analytical column (from 87.5%:12.5% to 10%:90%). Detection was obtained using diode array in the range 190-350 nm, monitoring the signal at 248 nm and checking for quality control and assurance with additional qualifying signals. Concentrations of various PhACs were quantified by comparison with signals of pure standard solutions. Due to the lack of appropriate Certified Standard Reference Materials (SRMs), recovery for each compound was estimated on samples of control mussels (n=10) spiked with various concentrations of investigated molecules According to EU standards 2002/657/EC, retention time of all analytes are comparable with those obtained from the calibration standard in spiked mussels, within a margin of  $\pm 2,5\%$ .

The parameters related to the signals detection are reported in the Table SM3, including the retention time (RT), the wavelength of both main signals and qualifiers (2 for each compounds). The relative LOD, LOQ, minimum (MIN), median and maximum (MAX) values are also included. Reproducibility, recovery and RSD for each compound were determined adding aliquots of know concentrations of pure standard in mussels samples: For each compound, 5 levels of concentrations were tested on 5 samples (each constituted by 5 organisms) and the obtained data are included in the Table SM4.

The following identification criteria were applied for the detection of each analytes: 1) retention time (RT); for each compound the RT is verified using the chromatogram relating to the main signal and in those of at least two signals used as qualifiers. The RTs were previously determined through the separation of pure standard solutions with known concentration and selected in a time window equal to  $\pm 2.5\%$  of the RT itself. The verification of the RT was daily checked, corresponding to each individual analytical session, after fresh mobile phase solutions are prepared. 2) at least two qualifying signals were used for the verification and determination of each of the components. The qualifiers were chosen from the signals that ensure a value at least of 50% of the main signal, except for one of the two AMP qualifiers: the noise of background lead to select a signal in a cleaner chromatographic region, with a value  $< 50\%$ . For the same reason (influence of background) one of selected qualifiers for LOR, is characterized by a value higher than the main signal. The relative relationship between the main signal and that of the qualifiers was determined after calibrations

carried out with solutions of pure standards at a known concentration (at least 10 calibration points, each characterized by at least 5 replicates); the calibrations were periodically checked at each analytical session. The peaks for each analyte were accepted if both the selected qualifiers guarantee a signal equivalent to the ratio determined after calibration  $\pm 20\%$  of percentage variation; 3) each peak was accepted if the main signal and those of the qualifiers are sufficiently distinguishable from the background, with a peak separated for at least half of the height from any interfering signals; in any case, only peaks with a signal / noise ratio of at least 10/1 are accepted. 4) for the compounds that are determined by fluorescence as the main signal, i.e. IBU, PAR, VAL, in addition to the qualifying signals, cross check of signals obtained by DAD detector was checked; 5) for each compound, the UV/VIS absorption spectrum obtained by the DAD was compared with that of appropriate standard solutions and with that of mussel samples added with known aliquots of pure standards. 6) for compounds detected with DAD, the peak purity was evaluated through the specific software provided by Agilent Technologies (ChemStation Edition-OpenLAB CDS, Rev.C.01.03[37]), comparing the spectra of standard and sample solutions.

The water content in mussels tissues was determined by the measurement of wet weight and dry weight ratio in 5 replicates (each constituted by 5 organisms), for each sampling period and site as reported in Table SM5; final concentrations of detected pharmaceuticals were normalized and expressed as ng/g dry weight (d.w.). Considering these analytical conditions and the described preparation procedures, the minimum measurable amounts (Limit of Quantification, LOQ) in mussels tissues were 1 ng/g dry weight (d.w.) for AMP, 1.37 ng/g d.w. for DIC, 8 ng/g d.w. for IBU, 0.86 ng/g d.w. for KET, 2.10 ng/g d.w. for NIM, 1.03 ng/g d.w. for CBZ, 0.43 ng/g d.w. for LOR, 0.95 ng/g d.w. for PAR and 0.49 ng/g d.w. for VAL (Table SM3). All those values always ensure an appropriate analytical accuracy.

1 *Table SMI. General characteristics of sampling sites in both the Adriatic and Tyrrhenian Sea.*

2

Site	Location	Area	Latitude	Longitude	Characteristic	Year	Sampling period
S1	Senigallia	Adriatic Sea	43° 43' 14.93" N	13° 13' 33.30" E	Public beach	2014	Summer, Autumn
						2015	Spring, Summer, Autumn, Winter
						2016	Spring, Summer, Autumn, Winter
						2017	Spring, Summer
S2	Torrette	Adriatic Sea	43° 36' 42.28" N	13° 27' 13.31" E	Public beach	2014	Summer, Autumn
						2015	Spring, Summer, Autumn, Winter
						2016	Spring, Summer, Autumn, Winter
						2017	Spring, Summer
S3	Portonovo	Adriatic Sea	43° 34' 51.72" N	13° 34' 22.91" E	Public beach	2014	Summer, Autumn
						2015	Spring, Summer, Autumn, Winter
						2016	Spring, Summer, Autumn, Winter
						2017	Spring, Summer
S4	Fiorenzuola	Adriatic Sea	43° 57' 08.00" N	12° 49' 51.00" E	Natural park	2017	Spring, Summer, Autumn
S5	Baia Flaminia	Adriatic Sea	43° 55' 25.60" N	12° 53' 58.73" E	Canal harbour	2017	Spring, Summer, Autumn
S6	Tripodi	Adriatic Sea	43° 58' 29.00" N	12° 54' 51.10" E	Off-shore (7 NM)	2017	Spring, Summer, Autumn
S7	Vasto	Adriatic Sea	42° 03' 00.00" N	14° 55' 12.00" E	Mussel farm	2016	Summer
S8	Off-shore platform	Adriatic Sea	42° 12' 11.16" N	14° 58' 14.88" E	Off-shore (10 NM)	2016	Summer
S9	La Spezia	Tyrrhenian Sea	44° 01' 55.36" N	09° 52' 38.82" E	Mussel farm	2016	Winter
S10	Gombo	Tyrrhenian Sea	43° 43' 29.19" N	10° 14' 39.91" E	Natural Park	2016	Winter
S11	Fiume Morto	Tyrrhenian Sea	43° 44' 43.62" N	10° 12' 18.06" E	Natural Park	2016	Winter
S12	Livorno	Tyrrhenian Sea	43° 32' 24.39" N	10° 17' 51.97" E	Harbour	2016	Winter
						2017	Autumn
S13	Forte dei Marmi	Tyrrhenian Sea	43° 57' 22.07" N	10° 09' 01.33" E	Public beach	2017	Spring, Summer
S14	Lido di Camaiore	Tyrrhenian Sea	43° 53' 48.53" N	10° 12' 58.05" E	Public beach	2017	Spring, Summer

3

4 *Table SM2: Main chromatographic conditions.*

5

Method	Coditions	Mobile phase	%	Detection	N° Channels	Duration (min)
Method 1	Isocratic	Ultra-pure water	26	DAD / FLD	6 + 3	20
		Acetonitrile	42			
		Buffer 1*	32			
Method 2	Gradient	Ultra-pure water	35 to 0	DAD / FLD	6 + 3	27
		Acetonitrile	30 to 65			
		Buffer 1*	35 to 35			
Method 3	Isocratic	Methanol	12.5	DAD	3	6
		Buffer 2**	87.5			

6

7 Table SM3: Detection parameters, including the retention times (RTs ± RDS), wavelength of both Main and Qualifier (2) signals, relative responsiveness of qualifier  
 8 (±RDS), LOD and LOQ (±RDS and CV%), minimum, median and maximum obtained values in the present application.

9

Compound		ACETAMINOPHEN	CARBAMAZEPINE	DICLOFENAC	IBUPROFEN	KETOPROFEN	LORMETAZEPAM	NIMESULIDE	PAROXETINE	VALSARTAN
ID		AMP	CBZ	DIC	IBU	KET	LOR	NIM	PAR	VAL
Method*		M3	M1	M1	M2	M1	M2	M2	M2	M1
Retention time	(min)	4.28 ± 0.10	2.70 ± 0.06	12.70 ± 0.32	18.50 ± 0.45	5.30 ± 0.12	12.10 ± 0.30	16.10 ± 0.40	5.32 ± 0.12	6.70 ± 0.16
Main signal	(nm)	DAD: 248	DAD: 286	DAD: 276	FLD: Ec 296, Em 338	DAD: 250	DAD: 232	DAD: 298	FLD: Ec 296, Em 338	FLD: Ec 250, Em 380
Qualifier 1	(nm)	268	294	266	Ec: 296, Em: 326	266	236	274	Ec: 296, Em: 326	Ec: 250, Em: 360
Qualifier 1	Relative sig. (%)	37 ± 24%	88 ± 2.4%	86 ± 27%	54 ± 9.7%	85 ± 3.8%	93 ± 16%	64 ± 4.4%	73 ± 31%	75 ± 6.8%
Qualifier 2	(nm)	228	276	294	Ec: 296, Em: 350	276	200	348	Ec: 296, Em: 350	Ec: 250, Em: 410
Qualifier 2	Relative sig. (%)	80 ± 2.4%	90 ± 8.8%	71 ± 9.8%	65 ± 2.2%	53 ± 2.7%	115 ± 31%	72 ± 4.4%	90 ± 25%	64 ± 7.5%
LOD (N=10)	(ng)	0.60 ± 0.12	0.62 ± 0.12	0.82 ± 0.16	4.80 ± 0.96	0.51 ± 0.10	0.26 ± 0.05	1.26 ± 0.25	0.57 ± 0.11	0.29 ± 0.05
LOD (N=10)	(ng/mL)	0.30 ± 0.06	0.31 ± 0.06	0.41 ± 0.08	2.40 ± 0.48	0.25 ± 0.05	0.13 ± 0.02	0.63 ± 0.12	0.28 ± 0.05	0.14 ± 0.02
LOQ (N=10)	(ng/g d.w.)	1.00 ± 0.20	1.03 ± 0.20	1.37 ± 0.27	8.00 ± 1.60	0.86 ± 0.17	0.43 ± 0.08	2.10 ± 0.42	0.95 ± 0.19	0.49 ± 0.09
LOQ (N=10)	CV%	20.0%	19.4%	19.7%	20.0%	19.8%	18.6%	20.0%	20.0%	18.4%
MIN value	(ng/g d.w.)	< 1	< 1.03	< 1.37	< 8	< 0.86	< 0.43	< 2.1	< 0.95	< 0.49
MEDIAN value	(ng/g d.w.)	< 1	111	< 1.37	< 8	< 0.86	< 0.43	< 2.1	< 0.95	< 0.49
MAX value	(ng/g d.w.)	< 1	821	443	105	< 0.86	895	301	81	10

10

11 \*See the Table SM2 for method specifications

12 Table SM4: Reproducibility and recovery of results based on 5 concentrations levels (for each level, N=5).

13

			ACETAMINOPHEN	CARBAMAZEPINE	DICLOFENAC	IBUPROFEN	KETOPROFEN	LORMETAZEPAM	NIMESULIDE	PAROXETINE	VALSARTAN
Concentration Level 1	Nominal	(ng/g d.w.)	5.28	4.92	6.60	31.44	4.48	2.44	8.44	4.32	2.09
	Measured	(ng/g d.w.)	5.01 ± 0.13	4.68 ± 0.10	6.32 ± 0.07	29.88 ± 0.56	4.28 ± 0.11	2.34 ± 0.03	8.03 ± 0.21	4.17 ± 0.10	1.99 ± 0.04
	Measured	CV%	2.64%	2.32%	1.25%	1.89%	2.66%	1.69%	2.62%	2.51%	2.46%
	Recovery	%	95.0 ± 2.5%	95.2 ± 2.2%	95.8 ± 1.1%	95.0 ± 1.7%	95.5 ± 2.5%	95.9 ± 1.6%	95.1 ± 2.4%	96.5 ± 2.4%	95.2 ± 2.3%
Concentration Level 2	Nominal	(ng/g d.w.)	6.60	6.15	8.25	39.30	5.60	3.05	10.55	5.40	2.62
	Measured	(ng/g d.w.)	6.32 ± 0.09	5.85 ± 0.09	7.88 ± 0.10	37.50 ± 0.76	5.34 ± 0.11	2.92 ± 0.05	10.07 ± 0.19	5.15 ± 0.10	2.50 ± 0.04
	Measured	CV%	1.54%	1.71%	1.30%	2.05%	2.06%	2.04%	1.94%	2.02%	1.98%
	Recovery	%	95.9 ± 1.4%	95.1 ± 1.6%	95.5 ± 1.2%	95.4 ± 1.9%	95.4 ± 1.9%	96.0 ± 1.9%	95.4 ± 1.8%	95.4 ± 1.9%	95.6 ± 1.8%
Concentration Level 3	Nominal	(ng/g d.w.)	7.92	7.38	9.90	47.16	6.72	3.66	12.66	6.48	3.14
	Measured	(ng/g d.w.)	7.60 ± 0.13	7.02 ± 0.11	9.54 ± 0.19	45.36 ± 0.66	6.45 ± 0.12	3.49 ± 0.06	12.06 ± 0.19	6.18 ± 0.08	3.00 ± 0.04
	Measured	CV%	1.78%	1.61%	2.04%	1.46%	1.99%	1.91%	1.63%	1.45%	1.58%
	Recovery	%	96.0 ± 1.7%	95.1 ± 1.5%	96.4 ± 1.9%	96.1 ± 1.4%	95.9 ± 1.9%	95.4 ± 1.8%	95.3 ± 1.5%	95.3 ± 1.3%	95.8 ± 1.5%
Concentration Level 4	Nominal	(ng/g d.w.)	9.24	8.61	11.55	55.02	7.84	4.27	14.77	7.56	3.66
	Measured	(ng/g d.w.)	8.88 ± 0.16	8.26 ± 0.14	11.12 ± 0.18	53.03 ± 0.98	7.61 ± 0.06	4.14 ± 0.05	14.13 ± 0.19	7.23 ± 0.11	3.48 ± 0.04
	Measured	CV%	1.84%	1.73%	1.70%	1.86%	0.91%	1.29%	1.36%	1.59%	1.33%
	Recovery	%	96.1 ± 1.7%	95.9 ± 1.6%	96.3 ± 1.6%	96.3 ± 1.7%	97.1 ± 0.8%	97.0 ± 1.2%	95.6 ± 1.2%	95.7 ± 1.5%	95.2 ± 1.2%
Concentration Level 5	Nominal	(ng/g d.w.)	10.56	9.84	13.20	62.88	8.96	4.88	16.88	8.64	4.18
	Measured	(ng/g d.w.)	10.16 ± 0.18	9.45 ± 0.14	12.72 ± 0.18	60.52 ± 0.96	8.59 ± 0.12	4.68 ± 0.08	16.09 ± 0.25	8.29 ± 0.11	4.00 ± 0.05
	Measured	CV%	1.81%	1.52%	1.43%	1.59%	1.46%	1.86%	1.60%	1.43%	1.34%
	Recovery	%	96.2 ± 1.7%	96.0 ± 1.4%	96.3 ± 1.3%	96.2 ± 1.5%	95.9 ± 1.3%	96.0 ± 1.7%	95.3 ± 1.5%	95.9 ± 1.3%	95.6 ± 1.2%
	R <sup>2</sup>		0.9942	0.9951	0.9956	0.9950	0.9947	0.9943	0.9950	0.9950	0.9955

14

15 Table SM5: Average fresh and dry weight of mussel tissues measured at various locations in different sampling  
 16 periods.

Site	Period	Year	Average Fresh weight (g)	Average Dry weight (g)	Average Ratio	CV%
S1	Summer	2014	3.10±0.03	0.64±0.07	4.57±0.57	11.7%
	Autumn	2014	3.00±0.26	0.63±0.05	5.09±0.48	10.0%
	Spring	2015	3.05±0.22	0.71±0.05	4.35±0.60	14.2%
	Summer	2015	3.20±0.06	0.62±0.04	5.16±0.55	11.4%
	Autumn	2015	3.10±0.15	0.66±0.08	4.71±0.58	12.1%
	Winter	2015	3.15±0.12	0.58±0.02	4.49±0.43	10.0%
	Spring	2016	3.28±0.05	0.68±0.07	4.82±0.50	12.4%
	Summer	2016	3.09±0.09	0.70±0.01	4.41±0.59	12.9%
	Autumn	2016	3.20±0.13	0.65±0.01	4.92±0.75	15.0%
	Winter	2016	3.40±0.11	0.70±0.03	4.86±0.83	17.3%
	Spring	2017	3.60±0.05	0.73±0.07	4.93±0.77	15.8%
	Summer	2017	3.24±0.18	0.63±0.02	5.14±0.69	13.0%
	Autumn	2017	3.08±0.21	0.70±0.05	4.40±0.56	12.8%
	Winter	2017	3.21±0.25	0.62±0.05	5.18±0.78	15.1%
S2	Summer	2014	3.09±0.13	0.65±0.02	4.75±0.74	15.9%
	Autumn	2014	3.28±0.08	0.70±0.05	4.68±0.77	16.2%
	Spring	2015	2.90±0.13	0.59±0.06	4.91±0.62	12.8%
	Summer	2015	3.10±0.05	0.61±0.03	5.08±0.75	14.7%
	Autumn	2015	3.02±0.23	0.64±0.06	4.72±0.50	10.8%
	Winter	2015	3.20±0.14	0.66±0.02	4.84±0.62	12.6%
	Spring	2016	3.12±0.07	0.70±0.01	4.45±0.54	12.6%
	Summer	2016	3.40±0.18	0.69±0.08	4.92±0.94	18.9%
	Autumn	2016	3.17±0.10	0.71±0.09	4.46±0.76	17.2%
	Winter	2016	3.09±0.12	0.63±0.05	4.90±0.56	11.9%
	Spring	2017	3.3±0.09	0.66±0.03	5.02±0.65	12.8%
	Summer	2017	3.18±0.05	0.61±0.04	5.21±0.73	13.9%
	Autumn	2017	3.24±0.16	0.76±0.06	4.26±0.64	14.7%
	Winter	2017	3.14±0.23	0.66±0.07	4.75±0.80	17.2%
S3	Summer	2014	3.18±0.07	0.70±0.02	4.54±0.68	14.6%
	Autumn	2014	3.24±0.03	0.63±0.02	5.14±0.52	10.2%
	Spring	2015	3.05±0.08	0.69±0.06	4.42±0.58	12.9%
	Summer	2015	3.12±0.03	0.60±0.02	5.22±0.63	11.7%
	Autumn	2015	2.5±0.11	0.48±0.01	5.20±0.73	13.7%
	Winter	2015	3.52±0.05	0.70±0.05	5.02±0.67	12.9%
	Spring	2016	3.27±0.06	0.64±0.07	5.10±0.52	10.0%
	Summer	2016	3.43±0.11	0.71±0.03	4.83±0.63	12.6%
	Autumn	2016	3.21±0.09	0.68±0.04	4.72±0.52	10.8%
	Winter	2016	3.08±0.17	0.60±0.08	5.13±0.79	15.2%
	Spring	2017	3.14±0.04	0.65±0.03	4.83±0.55	11.2%
	Summer	2017	3.22±0.16	0.71±0.08	4.53±0.81	17.5%
	Autumn	2017	3.14±0.09	0.68±0.06	4.98±0.68	13.0%
	Winter	2017	3.22±0.05	0.67±0.06	4.80±0.62	12.7%
S4	Spring	2017	3.13±0.10	0.60±0.03	5.21±0.73	13.8%
	Summer	2017	3.36±0.12	0.65±0.07	5.17±0.69	13.0%
	Autumn	2017	3.06±0.08	0.72±0.06	4.25±0.52	12.5%
S5	Spring	2017	3.41±0.14	0.80±0.05	4.26±0.69	16.0%
	Summer	2017	3.25±0.05	0.74±0.06	4.39±0.53	11.9%
	Autumn	2017	3.11±0.12	0.60±0.04	5.18±0.73	14.2%
S6	Spring	2017	3.03±0.08	0.71±0.03	4.26±0.65	15.4%
	Summer	2017	3.51±0.15	0.82±0.08	4.28±0.48	11.5%
	Autumn	2017	3.29±0.06	0.75±0.07	4.38±0.66	14.6%
S7	Summer	2016	3.34±0.18	0.79±0.03	4.23±0.78	18.2%
S8	Summer	2016	3.09±0.09	0.68±0.01	4.54±0.76	13.2%
S9	Winter	2016	3.22±0.14	0.75±0.06	4.30±0.71	16.2%
S10	Winter	2016	3.15±0.17	0.67±0.04	4.68±0.78	16.5%
S11	Winter	2016	3.42±0.09	0.70±0.07	4.89±0.74	14.8%
S12	Winter	2016	3.07±0.13	0.64±0.05	4.80±0.48	10.3%
	Autumn	2017	2.89±0.08	0.78±0.06	4.30±0.69	16.6%
S13	Spring	2017	3.35±0.14	0.76±0.08	4.41±0.78	17.3%
	Summer	2017	3.29±0.18	0.66±0.03	4.95±0.64	12.5%
S14	Spring	2017	3.41±0.04	0.62±0.01	5.53±0.67	12.0%
	Summer	2017	3.03±0.16	0.58±0.07	5.26±0.94	18.2%

Table SM6: Results of two-way analysis of variance for concentrations of pharmaceuticals in the whole tissues of *M. galloprovincialis* collected in Senigallia (S1), Torrette (S2) and Portonovo (S3) from 2014 to 2017. DIC: diclofenac,  $\Sigma$  NSAIDs: Total Non-Steroidal Anti-Inflammatory Drugs (sum of DIC, IBU and NIM), CBZ: carbamazepine, PAR: paroxetine, LOR: lorazepam,  $\Sigma$ PSY: Total Psychiatric Drugs (sum of CBZ, PAR and LOR), VAL: valsartan, dF, degree of freedom; F, F test; P, probability level; n.s. not significant, n.t. not tested.

VARIABLE	SITE	MONTH			YEAR			MONTHxYEAR		
		dF	F	p	dF	F	p	dF	F	p
Dic	S1	7	30.46983	p < 0.001	3	15.6858	p < 0.001	2	16.71058	p < 0.001
	S2	8	2.176708	p < 0.05	3	0.178904	n.s.	n.t.	n.t.	n.t.
	S3	8	3.794528	p < 0.01	3	3.445155	p < 0.05	2	3.976906	p < 0.05
$\Sigma$ NSAIDs	S1	7	7.316792	p < 0.001	3	2.86113	p < 0.001	2	7.059261	p < 0.01
	S2	8	4.409396	p < 0.001	3	4.196254	p < 0.05	2	0.728584	n.s.
	S3	8	3.026138	p < 0.01	3	2.421515	p < 0.01	2	2.363707	n.s.
Cbz	S1	5	49.47053	p < 0.001	2	10.30637	p < 0.001	1	0.861587	n.s.
	S2	6	271.3531	p < 0.001	2	578.3507	p < 0.001	1	21.24534	p < 0.001
	S3	6	11.12197	p < 0.001	2	18.74909	p < 0.001	1	15.01065	p < 0.001
Lor	S2	6	4.121298	p < 0.01	2	1.73088	n.s.	n.t.	n.t.	n.t.
Par	S1	5	1.746727	n.s.	2	1.64296	n.s.	n.t.	n.t.	n.t.
	S2	6	1.573198	n.s.	2	1.490586	n.s.	n.t.	n.t.	n.t.
	S3	6	4.076	p < 0.01	2	7.888001	p < 0.01	1	16.77622	p < 0.001
$\Sigma$ PSY	S1	5	46.09712	p < 0.001	2	11.81652	p < 0.001	1	5.89E-05	n.s.
	S2	6	18.48101	p < 0.001	2	26.41206	p < 0.001	1	0.480851	n.s.
	S3	6	5.119507	p < 0.001	2	1.886574	n.s.	n.t.	n.t.	n.t.
Val	S1	5	19.12311	p < 0.001	2	0.754014	n.s.	n.t.	n.t.	n.t.
	S2	6	31.22737	p < 0.001	2	19.27081	p < 0.001	1	0.31066	n.s.
	S3	6	7.626437	p < 0.001	2	24.26529	p < 0.001	1	0.718008	n.s.

Note: Ibuprofen and Nimesulide are not reported since the two-way ANOVA could not be performed given the high variability of obtained results.

Table SM7. Complete analytical data-set obtained in the present study. Concentrations of pharmaceuticals in the whole tissues of *M. galloprovincialis* collected in Senigallia (S1), Torrette (S2) and Portonovo (S3) from 2014 to 2017. Data are given as mean values  $\pm$  standard deviations ( $n=5$ ). NSAIDs: Non Steroidal Anti-Inflammatory Drugs; PSY: psychiatric drugs; AH: antihypertensive drug; DIC: diclofenac; IBU: ibuprofen; NIM: nimesulide;  $\Sigma$  NSAIDs: Total NSAIDs (sum of DIC, IBU and NIM); CBZ: carbamazepine; PAR: paroxetine; LOR: Lormetazepam;  $\Sigma$ PSY: Total PSY (sum of CBZ, PAR and LOR); VAL: valsartan; n.a. not analyzed. Values are expressed as ng/g dw for all the individual drugs while  $\Sigma$ NSAIDs and  $\Sigma$ PSY are expressed as nmol/g to normalize different molecular weights of different compounds.

Site	Year	Season	Month	NSAIDs				PSY			AH		
				DIC ng g-1 (d.w.)	IBU ng g-1 (d.w.)	NIM ng g-1 (d.w.)	$\Sigma$ NSAIDs nmol g-1 (d.w.)	CBZ ng g-1 (d.w.)	PAR ng g-1 (d.w.)	LOR ng g-1 (d.w.)	$\Sigma$ PSY nmol g-1 (d.w.)	VAL ng g-1 (d.w.)	
S1	2014	Summer	Jul	<1.4	<8.0	2.3 $\pm$ 2.2	0.01 $\pm$ 0.02	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
			Aug	1.4 $\pm$ 0.8	<8.0	2.2 $\pm$ 1.0	0.03 $\pm$ 0.00	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
		Autumn	Sep	27.8 $\pm$ 46.9	<8.0	<2.00	0.09 $\pm$ 0.16	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
			2015	Spring	Apr	29.6 $\pm$ 10.2	143.7 $\pm$ 242	<2.00	0.12 $\pm$ 0.03	n.a.	n.a.	n.a.	n.a.
		Summer	Jul	103.8 $\pm$ 27.9	<8.0	<2.00	0.35 $\pm$ 0.09	45.5 $\pm$ 14.72	16.66 $\pm$ 8.8	6.426 $\pm$ 8.5	0.26 $\pm$ 0.1	1.239 $\pm$ 2.0	
			Aug	<1.4	<8.0	<2.00	<0.004	151.1 $\pm$ 27.87	9.089 $\pm$ 4.5	<0.40	0.66 $\pm$ 0.1	3.195 $\pm$ 1.2	
		Autumn	Nov	<1.4	<8.0	<2.00	<0.004	279.6 $\pm$ 67.57	4.477 $\pm$ 2.5	<0.40	1.2 $\pm$ 0.3	5.965 $\pm$ 0.9	
			2016	Winter	Feb	<1.4	<8.0	80.6 $\pm$ 74.9	0.28 $\pm$ 0.24	228.2 $\pm$ 101.3	5.855 $\pm$ 5.5	<0.40	0.982 $\pm$ 0.4
		Spring	May	99.1 $\pm$ 24.0	<8.0	<2.00	0.33 $\pm$ 0.08	270.5 $\pm$ 107.4	1.645 $\pm$ 2.6	<0.40	1.15 $\pm$ 0.5	<0.5	
			Summer	Jul	2.5 $\pm$ 2.5	<8.0	<2.00	0.02 $\pm$ 0.02	32.73 $\pm$ 8.966	29.99 $\pm$ 17.0	<0.40	0.219 $\pm$ 0.1	0.938 $\pm$ 0.8
		Autumn	Oct	58.4 $\pm$ 55.5	14.95 $\pm$ 15.91	2.1 $\pm$ 2.1	0.26 $\pm$ 0.26	140.7 $\pm$ 23.94	4.501 $\pm$ 9.0	439.5 $\pm$ 77.0	2.19 $\pm$ 0.7	6.681 $\pm$ 1.1	
			2017	Spring	May	109.3 $\pm$ 50.7	<8.0	<2.00	0.37 $\pm$ 0.16	139.4 $\pm$ 57.8	5.329 $\pm$ 1.1	<0.40	0.605 $\pm$ 0.2
		Summer	Jul	<1.4	<8.0	<2.00	<0.004	21.9 $\pm$ 6.455	3.363 $\pm$ 5.4	2.38 $\pm$ 3.1	0.109 $\pm$ 0.0	0.521 $\pm$ 0.4	
	S2	2014	Summer	Jul	<1.4	<8.0	56.0	0.20	n.a.	n.a.	n.a.	n.a.	n.a.
Aug				1.7 $\pm$ 1.2	13.57 $\pm$ 10.6	5.8 $\pm$ 6.8	0.09 $\pm$ 0.04	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
		Autumn	Sep	<1.4	<8.0	<2.00	<0.004	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
			2015	Spring	Apr	27.2 $\pm$ 16.9	<8.0	<2.00	0.11 $\pm$ 0.05	n.a.	n.a.	n.a.	n.a.
		Summer	Jul	20.6 $\pm$ 27.3	<8.0	<2.00	0.07 $\pm$ 0.10	62.9 $\pm$ 7.709	2.667 $\pm$ 2.1	1.373 $\pm$ 1.6	0.277 $\pm$ 0.0	1.256 $\pm$ 0.8	
			Aug	<1.4	<8.0	61.0 $\pm$ 134.0	0.22 $\pm$ 0.43	34.6 $\pm$ 25.79	6.976 $\pm$ 5.7	18.94 $\pm$ 25.1	0.222 $\pm$ 0.2	<0.5	
		Autumn	Nov	<1.4	<8.0	<2.00	<0.004	299.7 $\pm$ 46.23	1.122 $\pm$ 1.1	<0.40	1.272 $\pm$ 0.2	5.431 $\pm$ 0.4	
			2016	Winter	Feb	<1.4	<8.0	<2.00	<0.004	181.8 $\pm$ 41.26	4.142 $\pm$ 3.6	<0.40	0.781 $\pm$ 0.2
		Spring	May	36.4 $\pm$ 35.1	<8.0	3.7 $\pm$ 4.0	0.14 $\pm$ 0.11	<1.0	<1.00	104.8 $\pm$ 105.9	0.314 $\pm$ 0.3	1.318 $\pm$ 1.1	
			Summer	Jul	14.0 $\pm$ 29.9	28.42 $\pm$ 19.7	<2.00	0.19 $\pm$ 0.07	<1.0	4.002 $\pm$ 5.3	<0.40	0.011 $\pm$ 0.0	1.802 $\pm$ 1.5
		Autumn	Oct	12.7 $\pm$ 26.9	9.424 $\pm$ 12.13	<2.00	0.09 $\pm$ 0.09	201.3 $\pm$ 35.15	3.976 $\pm$ 7.8	42.81 $\pm$ 24.7	0.99 $\pm$ 0.2	3.384 $\pm$ 0.8	
			2017	Winter	Dec	<1.4	27.86 $\pm$ 32.9	7.1 $\pm$ 10.8	0.16 $\pm$ 0.16	181.8 $\pm$ 84.92	2.119 $\pm$ 3.7	235.2 $\pm$ 218.4	1.476 $\pm$ 0.8
		Spring	May	6.5 $\pm$ 12.9	<8.0	<2.00	0.04 $\pm$ 0.04	216.8 $\pm$ 78.88	6.248 $\pm$ 4.0	2.159 $\pm$ 4.3	0.941 $\pm$ 0.3	<0.5	
			Summer	Jul	84.3 $\pm$ 82.1	<8.0	<2.00	0.29 $\pm$ 0.26	52.27 $\pm$ 31.37	1.049 $\pm$ 1.3	<0.40	0.225 $\pm$ 0.1	0.364 $\pm$ 0.3
S3	2014	Summer	Jul	<1.4	<8.0	6.7 $\pm$ 9.9	0.04 $\pm$ 0.03	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
			Aug	16.1 $\pm$ 14.7	9.398 $\pm$ 0.59	4.2 $\pm$ 2.5	0.11 $\pm$ 0.06	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
		Autumn	Sep	<1.4	<8.0	6.1 $\pm$ 4.4	0.04 $\pm$ 0.01	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
			2015	Spring	Apr	5.4 $\pm$ 8.1	<8.0	3.8 $\pm$ 2.6	0.05 $\pm$ 0.03	n.a.	n.a.	n.a.	n.a.
		Summer	Jul	171.1 $\pm$ 233.6	<8.0	<2.00	0.56 $\pm$ 0.73	76.09 $\pm$ 30.15	11.16 $\pm$ 7.8	2.181 $\pm$ 4.4	0.358 $\pm$ 0.1	1.771 $\pm$ 1.6	
			Aug	52.1 $\pm$ 37.5	<8.0	<2.00	0.19 $\pm$ 0.12	74.45 $\pm$ 24.02	2.26 $\pm$ 2.5	<0.40	0.322 $\pm$ 0.1	<0.5	
		Autumn	Nov	<1.4	<8.0	13.6 $\pm$ 28.1	0.07 $\pm$ 0.09	144.7 $\pm$ 30.55	4.959 $\pm$ 1.7	<0.40	0.626 $\pm$ 0.1	<0.5	
			2016	Winter	Feb	<1.4	<8.0	<2.00	<0.004	240.2 $\pm$ 39.07	4.681 $\pm$ 4.2	<0.40	1.03 $\pm$ 0.2
		Spring	May	53.6 $\pm$ 31.4	<8.0	4.6 $\pm$ 7.9	0.20 $\pm$ 0.11	<1.0	6.739 $\pm$ 14.0	288 $\pm$ 130.7	0.879 $\pm$ 0.4	1.774 $\pm$ 0.7	
			Summer	Jul	31.9 $\pm$ 32.9	<8.0	3.4 $\pm$ 3.8	0.13 $\pm$ 0.10	51.21 $\pm$ 46.36	<1.00	62.1 $\pm$ 138.4	0.403 $\pm$ 0.5	3.572 $\pm$ 0.6
		Autumn	Oct	34.8 $\pm$ 48.2	<8.0	<2.00	0.13 $\pm$ 0.15	181.6 $\pm$ 108.5	<1.00	207.6 $\pm$ 140.4	1.39 $\pm$ 0.6	4.588 $\pm$ 1.4	
			2017	Winter	Dec	10.5 $\pm$ 22.0	40.92 $\pm$ 50.95	<2.00	0.23 $\pm$ 0.23	147.8 $\pm$ 35.35	18.44 $\pm$ 21.2	137.5 $\pm$ 157.3	1.085 $\pm$ 0.4
		Spring	May	16.8 $\pm$ 36.1	<8.0	<2.00	0.08 $\pm$ 0.11	128.7 $\pm$ 54.98	1.581 $\pm$ 1.6	<0.40	0.55 $\pm$ 0.2	<0.5	
			Summer	Jul	82.0 $\pm$ 27.2	<8.0	<2.00	0.28 $\pm$ 0.09	35.18 $\pm$ 14.23	49.94 $\pm$ 22.2	<0.40	0.283 $\pm$ 0.1	<0.5
S4	2017	Spring	May	162.6 $\pm$ 115.3	<8.0	<2.00	0.53 $\pm$ 0.36	199.5 $\pm$ 117.1	<1.00	7.134 $\pm$ 10.1	0.866 $\pm$ 0.5	0.563 $\pm$ 0.2	
			Summer	Jul	<1.4	<8.0	2.2 $\pm$ 2.5	0.03 $\pm$ 0.01	212.1 $\pm$ 130.4	1.566 $\pm$ 2.4	104.3 $\pm$ 27.5	1.213 $\pm$ 0.5	0.505 $\pm$ 0.6
			Autumn	Sep	<1.4	<8.0	<2.00	<0.004	15.33 $\pm$ 6.353	<1.00	98.95 $\pm$ 68.1	0.361 $\pm$ 0.2	0.392 $\pm$ 0.2
S5	2017	Spring	May	231.1 $\pm$ 67.2	19.51 $\pm$ 34.67	3.0 $\pm$ 4.3	0.83 $\pm$ 0.22	283.2 $\pm$ 70.14	<1.00	50.97 $\pm$ 16.5	1.352 $\pm$ 0.3	0.519 $\pm$ 0.4	
			Summer	Jul	<1.4	<8.0	<2.00	<0.004	190.2 $\pm$ 79.1	2.027 $\pm$ 2.5	<0.40	0.811 $\pm$ 0.3	0.725 $\pm$ 0.7
			Autumn	Sep	<1.4	<8.0	2.3 $\pm$ 2.7	0.01 $\pm$ 0.02	30.18 $\pm$ 18.35	1.626 $\pm$ 2.6	89.28 $\pm$ 40.0	0.398 $\pm$ 0.1	0.573 $\pm$ 0.6
S6	2017	Spring	May	<1.4	<8.0	<2.00	<0.004	197.8 $\pm$ 35.82	1.041 $\pm$ 1.1	60.19 $\pm$ 43.3	1.019 $\pm$ 0.2	2.113 $\pm$ 0.9	
			Summer	Jul	<1.4	<8.0	<2.00	<0.004	128.8 $\pm$ 55.88	4.691 $\pm$ 5.8	96.12 $\pm$ 34.4	0.845 $\pm$ 0.2	<0.5
			Autumn	Sep	<1.4	<8.0	2.0 $\pm$ 1.7	0.01 $\pm$ 0.01	34.7 $\pm$ 30.31	<1.00	20.52 $\pm$ 9.2	0.209 $\pm$ 0.2	0.395 $\pm$ 0.3
S7	2016	Summer	Jul	52.9 $\pm$ 71.5	<8.0	2.1 $\pm$ 2.1	0.18 $\pm$ 0.24	73.58 $\pm$ 76.26	4.516 $\pm$ 9.0	165.5 $\pm$ 70.6	0.817 $\pm$ 0.5	5.619 $\pm$ 3.7	
			Aug	75.4 $\pm$ 57.9	<8.0	<2.00	0.26 $\pm$ 0.18	157 $\pm$ 105.8	4.97 $\pm$ 8.3	39.9 $\pm$ 36.6	0.797 $\pm$ 0.4	2.83 $\pm$ 0.9	
S9	2016	Winter	Dec	<1.4	22.99 $\pm$ 26.01	5.5 $\pm$ 2.9	0.13 $\pm$ 0.13	76.61 $\pm$ 59.85	<1.00	<0.40	0.326 $\pm$ 0.3	1.967 $\pm$ 3.8	
S10	2016	Winter	Dec	6.9 $\pm$ 13.8	12.28 $\pm$ 18.52	4.0 $\pm$ 6.6	0.09 $\pm$ 0.09	47.43 $\pm$ 17	<1.00	<0.40	0.203 $\pm$ 0.1	1.029 $\pm$ 0.5	
S11	2016	Winter	Dec	<1.4	14 $\pm$ 22.37	9.4 $\pm$ 8.1	0.09 $\pm$ 0.13	46.37 $\pm$ 21.82	2.784 $\pm$ 5.2	<0.40	0.204 $\pm$ 0.1	<0.5	
S12	2016	Winter	Dec	<1.4	17.45 $\pm$ 12.52	<2.00	0.08 $\pm$ 0.07	123.7 $\pm$ 26.1	<1.00	<0.40	0.526 $\pm$ 0.1	<0.5	
			Autumn	Sep	<1.4	<8.0	<2.00	<0.004	147.2 $\pm$ 37.74	5.275 $\pm$ 1.9	12.6 $\pm$ 9.3	0.674 $\pm$ 0.2	3.496 $\pm$ 0.7
S13	2017	Spring	Mar	280.1 $\pm$ 161.8	<8.0	<2.00	0.90 $\pm$ 0.51	563.3 $\pm$ 196.2	11.79 $\pm$ 8.7	<0.40	2.416 $\pm$ 0.8	1.067 $\pm$ 0.6	
			Summer	Aug	<1.4	<8.0	<2.00	<0.004	53.37 $\pm$ 40.03	4.82 $\pm$ 2.7	24.83 $\pm$ 24.2	0.313 $\pm$ 0.2	0.557 $\pm$ 0.2
S14	2017	Spring	Mar	<1.4	<8.0	<2.00	<0.004	309.2 $\pm$ 208.1	1.413 $\pm$ 2.1	205 $\pm$ 48.5	1.922 $\pm$ 1.0	<0.5	
			Summer	Aug	<1.4	<8.0	<2.00	<0.004	39.84 $\pm$ 18.22	6.719 $\pm$ 4.8	8.622 $\pm$ 6.3	0.212 $\pm$ 0.1	0.438 $\pm$ 0.3

## References

Mezzelani, M., Gorbi, S., Fattorini, D., d'Errico, G., Benedetti, M., Milan, M., Bargelloni, L., Regoli, F., 2016b. Transcriptional and cellular effects of non-Steroidal Anti-inflammatory drugs (NSAIDs) in experimentally exposed mussels, *Mytilus galloprovincialis*. *Aquat. Toxicol.* 180, 306–313. <https://doi.org/10.1016/j.aquatox.2016.10.006>

Mezzelani, M., Gorbi, S., Regoli, F., 2018a. Pharmaceuticals in the aquatic environments: evidence of emerged threat and future challenges for marine organisms. *Mar. Environ. Res.* 140, 41–60. <https://doi.org/10.1016/J.MARENRES.2018.05.001>.

Mezzelani, M., Gorbi, S., Fattorini, D., d'Errico, G., Consolandi, G., Milan, M., Bargelloni, L., Regoli, F., 2018b. Long-term exposure of *Mytilus galloprovincialis* to Diclofenac, Ibuprofen and Ketoprofen: insights into bioavailability, biomarkers and transcriptomic changes. *Chemosphere* 198, 238-248. <https://doi.org/10.1016/j.chemosphere.2018.01.148>

2002/657/EC: Commission Decision of 12 August 2002 implementing Council Directive 96/23/EC concerning the performance of analytical methods and the interpretation of results. *Official Journal of the European Communities* 17.8.2002. L 221, vol 45. ISSN: 0378-6978.